No retraction, correction or concern found when last checked on Oct 23, 2026.

Antimicrobial Peptides and Proteins: From Nature’s Reservoir to the Laboratory and Beyond

Tanumoy Sarkar, Monikha Chetia, Sunanda Chatterjee

Frontiers in Chemistry · 2021 · Review · CC BY

doi:10.3389/fchem.2021.691532

Abstract

Rapid rise of antimicrobial resistance against conventional antimicrobials, resurgence of multidrug resistant microbes and the slowdown in the development of new classes of antimicrobials, necessitates the urgent development of alternate classes of therapeutic molecules. Antimicrobial peptides (AMPs) are small proteins present in different lifeforms in nature that provide defense against microbial infections. They have been effective components of the host defense system for a very long time. The fact that the development of resistance by the microbes against the AMPs is relatively slower or delayed compared to that against the conventional antibiotics, makes them prospective alternative therapeutics of the future. Several thousands of AMPs have been isolated from various natural sources like microorganisms, plants, insects, crustaceans, animals, humans, etc. to date. However, only a few of them have been translated commercially to the market so far. This is because of some inherent drawbacks of the naturally obtained AMPs like 1) short half-life owing to the susceptibility to protease degradation, 2) inactivity at physiological salt concentrations, 3) cytotoxicity to host cells, 4) lack of appropriate strategies for sustained and targeted delivery of the AMPs. This has led to a surge of interest in the development of synthetic AMPs which would retain or improve the antimicrobial potency along with circumventing the disadvantages of the natural analogs. The development of synthetic AMPs is inspired by natural designs and sequences and strengthened by the fusion with various synthetic elements. Generation of the synthetic designs are based on various strategies like sequence truncation, mutation, cyclization and introduction of unnatural amino acids and synthons. In this review, we have described some of the AMPs isolated from the vast repertoire of natural sources, and subsequently described the various synthetic designs that have been developed based on the templates of natural AMPs or from de novo design to make commercially viable therapeutics of the future. This review entails the journey of the AMPs from their natural sources to the laboratory.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1In the wake of the post-pandemic resurgence, the greatest challenge faced by the civilized world are the antimicrobial infections. Rapidly growing antibiotic resistance accompanied by the slowdown of the development of the newer antibiotics in the recent past, is a reason for major concern. Scientists have been trying to look for alternate strategies or new classes of molecules to combat against the microbes. Antimicrobial peptides (AMPs) are small proteins present in a various plant and animal species that act as the first line of defense against the microbes. Their existence in nature for over millions of years and sustained capability to combat antimicrobial infections is a testimony of complete absence of or very slow development of resistance against them. This makes them specifically desirable in comparison to the antibiotics, which develop resistance pretty fast. The absence/slow development of resistance against microbes may be attributed to the presence of various modes/mechanisms of action of the AMPs against the bacteria in comparison to the fixed targets used by the antibiotics. Additionally, AMPs breakdown into amino acids unlike other therapeutics, which might generate potentially harmful metabolites.

2AMPs are produced as secondary metabolites and contain upto about 50 amino acid residues. They greatly vary in their sequence, secondary structural preferences, and in their modes of action. While a large variety of AMPs are cationic in nature (CAMPs) containing about +2 to +9 charge in them, there can be anionic AMPs (AAMPs) and completely hydrophobic AMPs as well. Secondary structures of AMPs vary from α-helices [magainin], protegrin, LL-37, β-sheets [α, β-defensins], drosomycin, thionins, plectasin, mixed αβ structures [RNase 2, RNase 3] to extended helices and loop structures (Figure 1). While membranolysis or disruption in the synthesis of the cell membrane/cell wall is considered as one of the major modes of action of the AMPs, other AMPs have intracellular targets and interfere with the vital intracellular processes. Some AMPs are known to have an immunomodulatory effect on the innate immune system of the host. AMPs can belong to various chemical classes like cationic, hydrophobic, amphipathic, disulfide bonded, cyclic and lipidated.

3Over the last couple of decades, thousands of AMPs have been isolated from different kingdoms of life. There are several databases like APD3, CAMP, DrAMP2.0 etc. which catalog the various AMPs that are known to date. AMPs are produced by microorganisms to protect them from other microbes. Some of the AMPs are shared by different classes of eukaryotes like plants and animals (defensins and cyclotides), others are only specific to plants (heveins), while others are specific to certain plant families (snakins). When compared to the other organisms, plants tend to have a higher amount of AMPs due to gene duplications or polyploidy. This may also be attributed to their immobility, which disables them to avoid the biotic and environmental conditions. Thionins, plant defensins, heveins, snakins are some plant-derived AMPs. Several AMPs like japonicin 2, nigrocin 2, temporin, dermaseptin, magainin, buforin II have been isolated from the amphibians, which have broad-spectrum antimicrobial activities against bacteria, fungi, yeast, protozoa and virus along with some potential in cancer therapy. Cepropin, thanatin, defensin, drosomycin, apidaecin, abaecin, melittin are some of the insect derived AMPs. Crustaceans produce several AMPs like callinectin, homarin, penaeidin, hyastatin, arasin. Mammals produce AMPs like defensins, histatins, LL-37, indolicidin, protegrins and lactoferrins. In animals, AMPs are isolated mostly from tissues and organs that are exposed to airborne pathogens like skin, eyes, ears, mouth, airways, lungs, intestines, urinary tract etc. and acts as the first line of innate immune defense.

4In spite of being a very promising alternative class of therapeutics, only a very few of the AMPs have been commercialized so far. This is owing to several inherent disadvantages of natural AMPs. These include limited quantities of AMPs isolated from the natural sources, uneconomic synthesis of longer AMP sequences, folding hurdles related to the natural AMPs, short half-life of the natural AMPs owing to protease degradability systemic toxicity and delivery issues to the target site. Inspired by nature and to address the shortcomings of the natural AMPs, research on synthetic AMPs has been explored extensively over the last few decades. In this review, we briefly recounted the journey of the natural AMPs from different kingdoms of life to the mainstream of synthetic research. As the field of AMP research is huge, and there are several elaborate reviews on the subtopics discussed here, this review does not claim to be exhaustive in nature. Instead, we have tried to represent and discuss 1) the various chemical classes of AMPs from different kingdoms of life which act as their natural reservoirs, 2) major shortcomings of the natural AMPs which limit their commercial applications, 3) how natural AMPs have influenced and inspired the synthetic AMP research and 4) how the synthetic AMP research addresses the shortcomings of the natural AMPs to make effective therapeutic antimicrobials of the future. In short, this review very briefly depicts the current scenario in the pursuit of the development of AMPs as future commercial therapeutic agents.

Natural Antimicrobial Peptides

5There are different ways in which AMPs can be classified. These rely on their physicochemical properties, secondary structure, sources, modes of action etc. In this review, we have broadly classified the AMPs into 1) cationic natural AMPs (Table 1), 2) Cyclic AMPs (Table 1) and 3) AMPs rich in specific amino acid residues like tryptophan (Trp), proline (Pro), histidine (His) and glycine (Gly) (Table 1).

Cationic Antimicrobial Peptides

6A large class of natural AMPs have positive charge (+2 to +9) due to the abundance of Lysine (Lys) and Arginine (Arg) residues in them (Figure 2 and Table 1). This gives an electrostatic advantage to the AMPs in binding to the negatively charged microbial membranes. Often these peptides have amphipathic structures where the positive part of the AMP is separated from the hydrophobic part of the AMP in the tertiary structure. Most of the cationic AMPs have membrane disruptive/lytic mode of action.

7Thionins are a class of small cationic plant AMPs rich in Lys, Arg and Cysteine (Cys) residues and are present in all the crucial plant tissues from endosperms to leaves. They are toxic against bacteria, fungi and yeasts. To date about 100 individual thionins have been isolated from about 15 plant species. Thionins have two antiparallel α helices and an antiparallel double stranded β-sheet with three or four disulfide bridges. Puroindolins (PINs) are small basic proteins isolated from wheat endosperms that have a unique Trp rich domain and five disulfide bridges. PINs have a conserved tertiary structure that is formed from four helices connected by variable loops, the tertiary structure being held together by five disulfide bridges. Antimicrobial activity of PINs is related to the interactions with the microbial membranes. Defensins are another class of small, cationic AMPs which are rich in Arg and Cys residues. They are present in various domains of life like plants, insects, animals and humans, and are highly active against a large range of microorganisms. Defensins have β-hairpin structures stabilized by three/four disulfide bonds. Defensins bind to membranes to form pore like membrane defects that lead to efflux of intracellular materials and eventual cell death. Plant defensins have antibacterial, antifungal, α-amylase and trypsin inhibitory activities. They are also active against yeast, oomycetes and necrotrophic pathogens. Additionally, they manifest anticancer and antiviral activities. Plant defensins have a conserved structure with three stranded β-sheet and a helix stabilized by four disulfide bridges. Human defensins are of three types-α, β and θ. There are six subclasses of α defensins containing three conserved disulfide connectivities in between Cys I−VI, Cys II−IV and Cys III−V. β-defensins are longer in sequence than the α defensins and have CysI−V, CysII−IV, CysIII−VI disulfide bond connectivities. There are various subclasses of human β-defensins (hBD). While hBD1 and hBD2 are rendered inactive in the presence of physiological salt concentrations, hBD3 retains its activity against Staphylococcus aureus (S. aureus) and vancomycin resistant Enterococcus faecium at physiological salt concentrations. Bioinformatics approaches have led to the identification of 23 additional human β-defensins from the disulfide bond connectivities, many of which have antimicrobial activities. Insect defensins are about 29–34 amino acids long with activity against both gram-positive and gram-negative bacteria, though the virulence against the gram-positive bacteria (S. aureus) is more than the gram-negative family.

8Cecropins are a family (seven subclasses) of small, cationic AMPs isolated from the hemolymph of giant silk moth Hyalophora cecropia. Cecropins are active against gram-positive, gram-negative bacteria and fungi. Cecropins form pores in the bacterial membranes, cause membrane depolarization and lysis. Bactericidin, lepidopteran and sarcotoxins are structurally related to cecropins. Melittin, a 26 amino acid residue long positively charged peptide hormone present in bee venom, is effective against several strains of bacteria. Melittin is also reported to have anti-inflammatory properties and activity against xanthomonas oryzae, a pathogenic bacteria causing destructive bacterial disease in rice. Melittin interacts with negative microbial membranes, leads to pore formation, efflux of intracellular material and eventual cell death. Melittin forms an amphipathic helical structure in the presence of microbial membrane mimics. The activity of melittin is highly dependent on a Pro residue in its primary sequence. Melittin causes apoptosis in C. albicans (Candida Albicans) through reactive oxygen species (ROS) mediated mitochondria and caspase pathway. Melittin exhibits strong synergistic effects with the conventional antibiotics against MDR isolates of Acenatibactor baumanni and Pseudomonas aeruginosa (P. aeruginosa) and effective antibacterial activity against Methicillin resistant S. aureus (MRSA) strains. Jelleines are a family of very small peptides (8-9 amino acid residues long) with +2 positive charge, which are isolated from the royal jelly of honey bees (Figure 2A). Jelleines I-III possess antimicrobial properties against yeast, fungi, gram-positive and gram-negative bacteria.

9Magainins are a family of small Gly rich cationic AMPs which are isolated from the skin of African clawed frog Xenopus laevis (Figure 2B). They are active against a large number of bacterial and fungal species and cause osmotic lysis of the protozoa. Magainins form amphipathic α-helical conformations in membrane lipid environments. Esculetins are a family of cationic AMPs (46 amino acids long) isolated from frog skin possessing broad-spectrum antimicrobial properties. Microbial membranes are the major target of this class of AMPs. Esculentin-2CHa is a 37 residue cationic antimicrobial peptide isolated from the skin of amphibians like Lithobates chiricahuensis. This peptide is predominantly α-helical in structure with broad-spectrum antimicrobial properties and low cytotoxicity. Temporins are yet another family of very small α-helical cationic AMPs, with low net positive charge, that are isolated from frog skin. They are highly potent against a wide range of pathogens like bacteria, fungi, viruses, yeasts and protozoa. Temporins are effective against gram-positive bacterial strains like MRSA and vancomycin resistant E. faecium and Enterococcus faecalis (E. faecalis). They are non-cytotoxic to mammalian cells and preserve their activity in the presence of serum. Nigrocin 1 and 2 isolated from the skin of Rana nigromaculata, manifested broad-spectrum antimicrobial activity against various microorganisms through membranolytic mode of action. Buforin II, a 21 amino acid residue long cationic AMP was derived from another less active AMP called Buforin I, isolated from Asian toad Bufo bufo garagrizans. Buforin II has broad-spectrum antimicrobial activity. Buforin II is non membranolytic and has a very strong affinity for the DNA and the RNA present in the cells. Buforin II has a helix-hinge-helix structure with the hinge at Pro11 residue. N terminal helix contains residues 5–10, while the C terminal helix spans across residues 12–21. Systematic structure activity studies revealed that the α-helical content of the peptide is critical for the antimicrobial potency of Buforin. Additionally, Pro hinge is extremely important for the cell-penetrating ability of the peptide. Mutation of this Pro converted the peptide into a regular membrane active AMP.

10Cathelicidins are a class of human AMPs which are basic in nature. The mature protein was isolated from the neutrophils, human skin and sweat. The peptide contains 37 amino acids and starts with a di-Leucine (Leu) (LL) unit and hence is called LL-37 peptides. LL-37 is active against a whole range of bacteria like Escherichia Coli (E. coli), S. aureus, P. aeruginosa and others. Hepcidins are cationic AMPs, 20–25 residues long with low positive charges and are highly disulfide bridged. Human Liver expressed AMP (LEAP-1) was discovered from human blood filtrate and urine and was named as Hepcidin 25. It is involved in the iron homeostasis in the body. AMP LEAP-2 is 40 amino acid residues long and does not have any role in iron regulation of the body.

11Some human proteins are antimicrobial in nature. Lysozyme, a positively charged enzyme that is present in animals, forms part of the innate immune system. Lysozyme is a glycosidic hydrolase that catalyses the hydrolysis of 1-4 β-linkages in between the N acetyl muramic acid and N acetyl D glucosamine residues in peptidoglycan that forms active components of the gram-positive bacterial cell wall. This hydrolysis compromises the integrity of the cell wall and causes lysis of the cell. Lysozyme is present abundantly in the secretions like tears, saliva, mucous, human milk, in macrophages and in neutrophils. Five of the eight ribonucleases have antimicrobial activity. RNase 2 and RNase 3 are both cationic proteins which have anti-parasitic and antiviral activity. RNase 3 also possesses bacterial agglutinating property. RNase 7 isolated from human skin is active against bacteria and yeast even at 4°C and is one of the most abundant innate defense peptide present in the urinary tract. RNase 5 is found to have toxic effects against gram-positive bacteria and fungi.

Cyclic Antimicrobial Peptides

12Cyclic AMPs derived from microbes are produced by non-ribosomal pathways by non-ribosomal protein synthetases (NRPs). They contain both proteinogenic and unnatural amino acid residues in them. Functional diversity of these molecules are enhanced by the introduction of various chemical modifications, some of which are epimerization, N-methylation, and heterocyclization. A large number of cyclic peptides have been isolated from natural resources (Figure 3; Table 1). Cyclic AMPs disrupt the structural integrity of the cells, by disrupting the membrane or targeting the biosynthesis of components of the microbial cell envelope like chitin, glucan, mannoproteins and sphingolipids. Some cyclic AMPs bind to the membrane and cause membranolysis, efflux of intracellular materials and cell death, while others bind to the membrane, traverse them and act upon specific membrane bound structures like ion channels, transporters and receptors. Natural cyclic peptides can be classified depending on the mode of cyclization (Figure 4) or their physicochemical properties. Homodetic cyclic AMPs are formed from the cyclization in between the terminal amino group and the carboxylic acid group. Argyrin B, guangomide, valinomycin (Figure 3A) are some representative examples of homodetic cyclic AMPs. Heterodectic cyclic AMPs are formed from the cyclization in between the side chains of two amino acid residues or in between side chain of one amino acid residue and a terminal amino/carboxylic acid group. Coibamide A, didemnin B, selenamide, luzopeptin are some of the representative examples of this class. Complex cyclic peptides are formed from the mixture of homodetic and heterodetic linkages and may be bicyclic in nature as in the case of amatoxins, amanitin (Figure 3B), phalloidin and triostin A. Cyclic peptides can be charged as in gramicidine S (Figure 3C), polymyxin B (Figure 3D) and bactenecin, non-polar as in argyrin B, aureobasidin and guanomide A, of mixed polarities as in kahalilide F, largamide and pseudodesmin A or containing cyclic cysteine knot (CCK) like kalata B1.

13Cyclic Lipopeptides (CLPs) contain a fatty acid tail attached to a cyclic peptide skeleton. These peptides possess broad-spectrum antifungal and antibiotic properties. They mostly act through membrane integration and formation of pores, thereby causing the leakage of the intracellular components and causing eventual cell death. Syringomycins and syringopeptides derived from Pseudomonas syringae, possess strong inhibitory activity against the growth of gram-positive bacteria, mycelia and antagonistic property against apple scab causing agent. Lipodepsipeptide Tolaasin D derived from Pseudomonas tolaasi prevents growth of Rhizoctania solani and gram-positive bacteria Rhodococcus fascians. Gram-negative bacteria Pseudomonas fluorescence produces several classes of cyclic AMPs. Pseudophomins A and B produced by pseudomonas fluorescens BRG100 significantly inhibit the growth of Phoma lingam, Alternaria brassicae and Sclerotinia sclerotiorum. Massetolide A produced by P. fluorescens SS101 possesses a biosurfactant property that affects plant pathogenic oomycetes. Amphisin, lokisin, tensin, and viscosinamide produced by P. fluorescens spp. possess in vitro antagonistic activities against the oomycete Pythium ultimum and the basidiomycete Rhizoctonia solani (R. solani). Bacillus species are major producers of CLP’s. Fusaricidins, iturins (Figure 3E), fengycins, polymixins, and agrastatins have been identified in culture extracts of several species of Bacillus. These CLPs are composed of seven (surfactins (Figure 3F), iturins) or ten (fengycins) α-amino acids linked to one unique β-amino (iturins) or β-hydroxy (surfactins, fengycins) fatty acid. The carbon numbers of β-amino fatty acid chain in surfactins, iturins, and fengycins are C13-C16, C14-C17, and C14-C18, respectively. Multiple derivatives of each lipopeptide family are usually co-produced by a strain. Iturins have antifungal activity against plant pathogens by pore formation in the cell membranes, causing an efflux of potassium and other vital ions eventually causing cell death. Fengycin type of cyclic peptides produced by B. subtilis (Bacillus subtilis) M4 prevents the mycelial growths of Fusarium oxysporum, R. solani and B. cinerea and prevents grey mold disease of apples caused by B. cinerea during storage. B. subtilis CMB32 produces iturin A, fengycin and surfactin A, which are able to suppress the growth of Colletotrichum gloeosporioides, the causative agent of anthracnose in a variety of crops. Surfactins produced by the Bacillus subtlis are one of the most effective bio-surfactant known till date and is known to have strong antimicrobial activity against C. albicans, Lactococcus lacti subsp. Lactis, Mycobacterium smegmatis, S. aureus, and Streptococcus mutant. Balliomycin produced by Bacillus species contains seven α-amino acids and β-amino fatty acids with 14–16 carbon atoms and can control a broad range of plant diseases. Mycosubtilin are heptapeptides containing alternating D and L amino acid residues closed by a β amino acid linkage. B. subtilis strains overproducing mycosubtilin are effective in controlling Pythium damping off on tomato plants than the parent strain. Polymixin B produced by the Paenibacillus sp. strain B2 have antifungal activity against root pathogenic fungus Fusarium solani and Fusarium acuminatum. Fusaridins are a group of depsipeptides produced by the Paenibacillus polymyxa E681 that control the Phytopthora blight infection in red pepper caused by Phytopthora capsica. Antibiotic Agrastatin A produced by B. subtilis AQ713 has a broad fungicidal spectrum in vitro. Gramicidin S produced by Brevibacillus Brevis has both antifungal activity and sporicidal activity. Daptomycin is a CLP antibiotic that is isolated from soil bacteria Streptomyces roseosporus. It is used in treating life threatening infections caused by gram-positive bacteria including MRSA and vancomycin resistant Enterococci. Daptomycin has a unique mechanism of action that leads to the destruction of membrane potential. It is commercially available as a peptide antibiotic drug. Several cyclopeptides are produced by Streptomyces species. Valinomycin, first identified from Streptomyces griseus has insecticidal, acaricidal, antifungal and antioomecyte activity. It acts as an ionophore and modulates the transport of potassium ions across biological membranes.

14Some natural cyclic AMPs block the biosynthesis of the cellular components. Chitin is a linear homopolymer of β-(1,4)-linked N-acetylglucosamine (GlcNAc) residues, and a major component of the fungal cell walls. Polyoxins and Nikkomycins are nucleoside peptide antibiotics that are competitive inhibitors of chitin synthase. Arthrichitin is a cyclic depsipeptide that inhibits chitin biosynthesis and works as an antifungal agent. Thiopeptide antibiotics are an important class of natural products that are formed from the post‐translational modifications of the ribosomally synthesized peptides. Cyclothiazomycin is a typical example that has a unique bridged macrocyclic structure derived from an 18 amino acid residue peptide. Cyclothiazomycin B1 produced by Streptomyces species acts as an antifungal cyclic thiopeptide that binds to chitin in the fungal cell wall and disrupts the crystallization of the chitin chain. This mechanism inhibits the growth of filamentous fungi and causes swelling of the hyphae and the spores. Glucans are homopolymers of glucose that form a network of fibrils around the fungal cell that helps to maintain the mechanical strength and the osmotic resistance of the fungal cell wall. The enzyme β-(1,3)-glucan synthase catalyzes polymerization of glucan. Neopeptins, produced by Streptomyces species have potent antifungal properties inhibiting mannoprotein, proteoheteroglycan and β-1-3-glycan synthases found in Sacharomyces cerevisiae. Growth of several microbes like Glomerella cingulata, Pleomorphomonas oryzae (P. oryzae), Cochliobolus miyabeanus, and Colletotrichum lagenaium can be completely inhibited by neopeptins. Aureobasidins are cyclic depsipeptide antifungal antibiotics that are produced from Aureobasidium pullulans. These are composed of eight lipophilic amino acid residues and one α-hydroxy acid, )) and are effective against a large range of fungi and protozoa. Aureobasidin A inhibits inositol phosphorylceramide (IPC) synthase, a key enzyme catalyzing sphingolipid synthesis in fungi.

15Cyclotides are groups of homodectic circular proteins that are isolated from plants and animals. Cyclotides have high sequence similarity. They contain three intramolecular disulfide bridges arranged in the form of a CCK. The CCK provides cyclotides with exceptional stability towards various proteolytic and degradative processes. Kalata B8 isolated from Oldenlandia affins has a diverse range of biological activities, including uterotonic, anti-HIV, antimicrobial, insecticidal, antihelmintic, and molluscidal properties. Kalata B1 interacts with the phosphotidylethanolamine phospholipid present in the membranes leading to membrane bending and vesicle formation. Hevein is a small Cys rich chitin binding protein that is present in the lutoid bodies of the rubber tree, that inhibits the hyphal growth of fungi. Different hevein like proteins with antimicrobial properties have been isolated from other plants. These peptides are small, 20–40 amino acids long, rich in Cys and Gly residues at conserved positions. Hevein like peptides have eight, six or ten Cys residues in them, giving rise to conserved disulfide bridges.

16Ranacyclins E and T are 17 residue cyclic peptides from amphibians that exhibit antimicrobial and antifungal activity. Theta (θ) defensins found in non-human primates are18 residue cyclic peptides formed by head-to-tail cyclization of the peptide. Like the α and the β-defensins, this class of peptides contain three disulfide bridges in between the Cys I-IV, Cys II-V and Cys III-IV. These genes are not expressed in humans due to the presence of a premature stop codon. Like monkey θ defensins, synthetic versions of the human analogs have anti-HIV activity.

Antimicrobial Peptides rich in specific amino acid residues (Tryptophan/Proline/Histidine/Glycine)

17Many AMPs have very high content of a certain amino acid residues like Trp, Pro, Gly or His (Figure 5; Table 3). These AMPs are usually extended having no regular structure and may be cationic or anionic in nature. Many of these peptides are known to have membrane permeability and intracellular targets.

18Trp residues are found in high proportions in a sub-class of short peptides (TrAMPs). The Trp residue usually appears near the C terminal end of the peptides. TrAMPs are also usually Arg rich. Most of the TrAMPs permeate bacterial membranes and acts on intracellular targets without disrupting membrane integrity. Only a very few like Indolicidin have membrane-disruptive activities. These peptides are active against different species of bacteria and fungi.

19Lactoferricins are mammalian TrAMPs, obtained from the peptide mediated digestion of lactoferrins which exhibit antimicrobial (against bacteria, fungi and viruses) and anticancer activity. Lactoferricins are cationic, amphipathic in nature. While the bovine lactoferricin is 25 amino acid residue long and mostly forms β-sheets, the human lactoferricin is 49 residues long and forms coiled coils. Indolicidin is a 13 residue (ILPWKWPWWPWRR-NH2) cationic TrAMP isolated from bovine neutrophils (Figure 5A). Indolicidin has broad-spectrum activity against bacteria, fungi, protozoa and virus. It is also active against MRSA, HIV virus and herpes simplex virus. The peptide directly inactivates the virus particles without being cytotoxic to the Vero cell line. Tritrpticin is another 13 amino acid residue long Tr-AMP that is derived from a precursor protein in the porcine bone marrow with high homology to the indolicidins. They have bactericidal and fungicidal activities against several clinical microorganisms.

20Pro rich AMPs (Pr-AMPs) usually have conserved repeats of Pro and Arg. They do not adopt amphipathic structure but β chain type polyproline or cyclic helix structure instead, as in Nisin and PR-39. Pr-AMPs are cationic peptides expressed in arthropods as well as animals. They have low sequence homology but high structural homology of about 30% Pro content and several Pro-Arg-Pro motifs. They usually kill bacteria by non-lytic mechanisms. Pro rich peptides like Drosocin, Pyrrhocoricin (Figure 5B), Metalnikowin 1 are known to inhibit protein biosynthesis by binding to the 70S ribosomal subunit, inhibiting heat shock proteins like DnaK and GroEL and binding to the lipopolysaccharides (LPS). In general Pro rich peptides enter into the cell through translocation of the inner membrane via a transporter mediated uptake mechanism by membrane protein SbmA. Several other Pr-AMPs like gonocin, apedaicin, drosocin are known to cross the blood brain barrier. Apidaecins are the first class of Pr-AMPs that were isolated from honey bees. The mature peptide is linear, 19 residues long, heat stable and non-helical in nature. They are known to be active against a large number of plant associated bacteria and human pathogens through a bactericidal pathway rather than a lytic process. Abaecin is a 32 amino acids long Pr-AMPs, isolated from honeybee Apis mellifera with strong antimicrobial and antifungal activity. Lebocins are 32 amino acids long glycosylated Pr-AMPs isolated from silkworm Bombyx mori. Lebocins have 41% sequence similarity with the baecin, a 34 residue antimicrobial peptide isolated from honeybee. Drosocin is a post-translationally modified PrAMP isolated from Drosophila melanogaster. Drosocin contains Pro-His repeats, along with a Threonine (Thr) residue and 5 N terminal residues critical for its activity. Drosocin is active against E. coli and fungi. Drosocin binds to bacterial DnaK, inhibiting cellular pathways and microbial ribosomes preventing protein translation. Pyrrhocoricin is a cyclic PrAMP isolated from Pyrrhocoris apterus that binds and promotes ATPase activity in the heat shock protein DnaK. Closely related to drosocin and abaecin in sequence and function, this acts as a delivery vehicle in transducing peptides across cell membranes of the important human parasite pathogen Cryptosporidium parvum. Metchnikowin, an immune inducible linear Pr-AMP peptide from D. megalogaster is selectively potent against gram-positive bacteria and fungi with no activity against gram-negative bacteria. Metchnikowin interacts with fungal enzyme β (1,3)-glucanosyl transferase Gel1, that is involved in the fungal cell wall synthesis. Diptericins (8 kDa) constitute a family of Pro and Gly rich AMP from Dipteran hemolymph proteins, which are about 82 amino acids long. Dipterin A is active against a few gram-negative bacteria like E. coli K12, Erwinia hericola T and Erwinia carotovora 113. This AMP acts on the cytoplasmic membrane of the growing bacteria. Bacternecin is a mammalian PrAMP that is found in mammalian species like cow, goat and sheep. It is referred to as Bac 5 or 7 depending on the molecular weight of the mature peptides. Bac5 (43 amino acids) and Bac7 (60 amino acids) enter bacterial cells through the SmbA transporter and work on the intracellular targets. In pigs, Pr-AMP corresponding to the Bac 7 is called PR-39 after the number of constituent amino acids.

21Human histatins are His rich AMPs. Histantins 1 and 3 are isolated from human saliva. Histatin 5 is present in the secretions of human submandibular and parotid glands. All the three histatins can kill pathogenic yeast C. albicans. Calcitermin C is a 15 residue AMP found in human airways and is effective against the gram-negative bacteria. It contains three His residues at the N terminus and a potential to adopt a helical conformation in the membranes.

22Several Gly rich peptides have been isolated from the bacteria, plants, insects, spiders, nematodes, fish and amphibians KDAMP is a keratin derived Gly rich AMP that is present in the bactericidal lysate fractions of the human corneal epithelial cells. Attacins are Gly rich proteins (10–22%) first isolated from Hyalophora ceropia and effective against gram-negative bacteria. Attacins are subdivided into subclasses A-F. Among these, Attacin A-D constitute the basic group while sub-classes E-F constitute acidic group of peptides. Attacins act via preventing the synthesis of the major outer membrane proteins, that disturb the integrity of the cell wall leading to formation of chains of bacteria. Attacins are mostly random coil in structure owing to the presence of high quantities of Gly residues. Persulcatusin is a Gly rich (20%) cationic AMP that is isolated from the mid-gut region of tick Ixodes persulcatus. This peptide adopts both α-helical and β-sheet structures that is stabilized by three disulfide bonds. Persulcatusin can inhibit the growth of Methycilin sensitive S. aureus (MSSA) and Methycilin resistant S. aureus (MSRA) and multi drug resistant (MDR) S. aureus strains. Ponericins are another family of Gly rich peptides isolated from the venom of the predatory ants. Ponericins are sub-divided into three classes depending on the primary sequence of the peptides. Ponericin G have sequence similarity with cecropin kind of peptides, ponericin W resembles melittin and ponericin L is similar with dermaceptins. They have α helical structures in cell membranes. Ponericins show hemolytic and insecticidal activities against cricket larvae.

Drawbacks of Natural Antimicrobial Peptides

23In spite of a very large repertoire of natural AMPs identified, isolated and characterized from various classes of living organisms, there is only a limited success in the commercialization of these peptides. This is due to several drawbacks of the natural AMPs.1) Long AMP sequences are economically and synthetically challenging for pharmaceutical scale synthesis.2) AMP sequences often contain complex disulfide bridges and CCKs which are challenging to be synthetically mimicked.3) Folding of synthetic AMPs into secondary structures (α-helical or β-sheet), critical for their activity, may be challenging, leading to their inactivity.4) Many AMPs that are produced in the other organisms may show toxicity and high immunogenicity when administered in humans, making them therapeutically inappropriate.5) Natural AMPs have short serum half-life due to their susceptibility to the protease degradation and physiological salt concentrations.6) Site directed delivery of AMPs to the site of infection is challenging.

241) Long AMP sequences are economically and synthetically challenging for pharmaceutical scale synthesis.

252) AMP sequences often contain complex disulfide bridges and CCKs which are challenging to be synthetically mimicked.

263) Folding of synthetic AMPs into secondary structures (α-helical or β-sheet), critical for their activity, may be challenging, leading to their inactivity.

274) Many AMPs that are produced in the other organisms may show toxicity and high immunogenicity when administered in humans, making them therapeutically inappropriate.

285) Natural AMPs have short serum half-life due to their susceptibility to the protease degradation and physiological salt concentrations.

296) Site directed delivery of AMPs to the site of infection is challenging.

30To overcome the shortcomings of the natural AMPs, there has been a surge of interest in generating synthetic AMPs. Several approaches have been adopted for the design of synthetic peptides as discussed below.1) Template based synthesis: Involves de novo sequencing of the synthetic peptides based on natural AMP sequences to improve their activity, cytotoxicity, proteolytic stability and salt tolerance This method includes truncation of sequences, mutation of specific amino acid residues, enrichment of primary sequence with certain types of residues, altering of the charge, hydrophobicity, secondary structure of the designed peptides, fusion of different peptide sequences, incorporation of unnatural amino acid residues, D amino acid residues, peptidomimetic fragments, cyclization, lipidation etc. with an intension to improvise on the shortcomings of the template natural AMP sequence. This is the most convenient and commonly practiced way of synthetic AMP design.2) Rigorous biophysical modelling: In this process, the prospective synthetic peptides are first modelled and are studied in hydrophobic membrane environments to have an atomistic idea of the designed peptides and their activities.3) Virtual screening: Virtual screening of the library of existing peptides is done to identify potential AMP sequences. This screening may be based on certain conserved primary sequence elements or secondary structural elements.

311) Template based synthesis: Involves de novo sequencing of the synthetic peptides based on natural AMP sequences to improve their activity, cytotoxicity, proteolytic stability and salt tolerance This method includes truncation of sequences, mutation of specific amino acid residues, enrichment of primary sequence with certain types of residues, altering of the charge, hydrophobicity, secondary structure of the designed peptides, fusion of different peptide sequences, incorporation of unnatural amino acid residues, D amino acid residues, peptidomimetic fragments, cyclization, lipidation etc. with an intension to improvise on the shortcomings of the template natural AMP sequence. This is the most convenient and commonly practiced way of synthetic AMP design.

322) Rigorous biophysical modelling: In this process, the prospective synthetic peptides are first modelled and are studied in hydrophobic membrane environments to have an atomistic idea of the designed peptides and their activities.

333) Virtual screening: Virtual screening of the library of existing peptides is done to identify potential AMP sequences. This screening may be based on certain conserved primary sequence elements or secondary structural elements.

34Truncation of the sequences introduces economic viability and facility in synthesis without compromising the antimicrobial potency. Improvement in the antimicrobial potency is attempted by mutation of/enrichment with certain amino acid residues, increase of the net charge/hydrophobicity of the peptide, optimization of the hydrophilic/lipophilic balance etc. Protease resistance of the AMPs is achieved by introducing chemical modifications like cyclization, terminal protection and incorporation of D-amino acid residues unnatural amino acid residues or peptidimimetic fragments. For efficient in vitro delivery, nanostructured AMP conjugates are designed. Hydrogels and nano-assemblies based on metal/metal oxide nanoparticles are being explored recently as prospective methods of AMP delivery.

Synthetic Antimicrobial Peptides

35In this section, we are going to describe some representative examples of synthetic AMPs which are cationic, cyclic and rich in amino acid residues like Trp, Pro, His and Gly (Table 2).

Synthetic Cationic Antimicrobial Peptides

36As cationic AMPs are the most abundant type of AMPs in nature, a lot of synthetic designs are based on cationic sequences. Blazyk et al. designed linear cationic peptides to demonstrate that amphipathicity in secondary structure was more important than the kind of secondary structure. (KIGAKI)3 which formed amphipathic β-sheet was more potent than (KIAGKIA)3 which formed a non-amphipathic α-helix upon membrane binding. In a subsequent study, two families (α-helices and β-sheets) of synthetic linear cationic peptides with same charge and C terminal amidation were studied. Only peptides able to form highly amphipathic structure (α-helical/β-sheet like) exhibited significant antimicrobial activities.

37Zhang et al. designed α-helical cationic AMPs with the variable number of Pro residues and demonstrated that Pro had a deactivating effect on the potency of the membranolytic cationic α-helical AMPs. Jadavpour et al. designed amphipathic Lys rich 7-mer, 14-mer and 21-mer peptides. 14 and 21 mer peptides exhibited high inhibition against gram-negative E. coli and P. aeruginosa and gram-positive S. aureus. 7-mers were inactive and unstructured, 14-mers peptides had low cytotoxicity while 21-mer peptides showed high cytotoxicity except for (KLGKKLG)3 and (KAAKKAA)3 against human erythrocytes as well as mouse fibroblasts. 14-mer and 21-mer peptides adopted helical structures as a function of the length of the peptides and the length of the hydrophobic side chain residues. The propensity of the AMPs to form helical conformation was proportional to their cytotoxicity and inversely proportional to their activity. Pandit et al. designed a series of short cationic heptapeptides. Peptides P4: LKWLRRL-NH2, P5: LRWLRRL-NH2 had broad-spectrum antimicrobial activity against several members of ESKAPE pathogens (E. coli, P. aeruginosa, Klebsiella pneumoniae (K. pneumoniae), S.typhi, and S.aureus) and pathogenic fungi like C. albicans and C.grubii. P4 and P5 were non-hemolytic, non-cytotoxic and membranolytic in their mode of action. In another study, Pandit et al. demonstrated that in a series of three 14 amino acid residue containing synthetic AMPs LL-14, VV-14 and ββ-14 having identical charge and sequence but differing in the hydrophobic amino acid residues, the length of the side-chain played an important role in the activity and the cytotoxicity of the peptides. Long hydrophobic side chain in Leu led to the best activity and highest cytotoxicity in LL-14 of all the three peptides. VV-14 was optimally active and non-cytotoxic (Figure 6A).While LL-14 and VV-14 formed α-helices in presence of membrane mimics, ββ-14 remained unstructured. In yet another study, a family of cationic, highly potent (against ESKAPE pathogens, C. albicans, Cryptococcus grubii (C. grubii)), non-cytotoxic undecapeptides were designed. Huang et al. designed a series of short triblock amphiphilic peptides (KnFmKn) with high potency against both gram-positive (S. aureus) and gram-negative bacteria (E. coli) with low cytotoxicity towards mammalian cell lines.

38Three cationic synthetic peptides JH8194(KRLFRRWQ), JH8195(KRLFRRLLFSMKKY) and JH8944(FKCKKVVISLRRY) were shown to have greater anticandidicidal effects than naturally occurring antifungals like Histantin 5 and Lactoferricin B. dF21-10K, the most potent AMP of the family of synthetic cationic peptides called kaxins could completely eradicate the preformed layer of biofilm formed by C. albicans and Candida tropicalis (C. tropicalis).

39Dendrimers are tree like molecules that have radially distributed layers of branches called generations. They can form covalent or noncovalent assembly of multiple ligands and are known to manifest the dendrimeric effect or non-linear enhancement of certain properties like drug potency or bioavailability. Polylysine dendrons (PLL) are a class of dendrimers proposed by Tam et al.. Such molecules have an inner matrix constituted of several layers of Lys connected by the α and ε-amino groups. The amino groups of Lys that are located on the surface can bind to one or more peptides. Recently, PLL dendrons have been used as scaffolds for carrying 2 or 4 ten residue peptide (RGRKVVRRKK) which exhibited a very strong activity against P. aeruginosa and a very low activity against fungi. Divalent and tetravalent dendrons expressed non-linear enhancement of activity against three reference Candida strains and two clinical isolates of C. albicans. Additionally, dendrimeric AMPs retain their activity against high salt concentrations or in the presence of trypsin, blood serum and tear fluid. Small dendrimeric cationic lipopeptides acquired selective activity against Candida sp. and exhibited low hemolytic activities. These lipopeptides produced potassium leakage from fungal cells, caused morphological alterations of the fungal cells and inhibited activity of candidal β (1,3) glucan synthase.

40Kallenbach and coworkers designed a dendrimeric peptide (RW)4D based on the short cationic peptide sequence (Figure 6B). The peptide exhibited activity against multi drug resistant strains of S. aureus and E. coli D31 (resistant against ampicillin and streptomycin) and Actinobacter baumanni. Additionally, the peptide was shown to inhibit E. coli 437 in the planktonic and biofilm states. Most bacteria in the preformed biofilm lost their viability after being treated with this peptide.

41N terminal of the Esculatin-1b, Esc (1–18) retained the antimicrobial property of the whole native peptide. Similarly, N-terminal 21 amino acid residue peptide from Esculatin 1a Esc(1–21)NH2 inhibited the growth of Saccharomyces cerevisiae by modulating the synthesis of proteins that are involved in the metabolism of cell membranes. The activity of Esc (1–21)NH2 against P. aeruginosa was salt tolerant. This led to its administration to P. aeruginosa keratitis in the murine model that caused a significant reduction of the infection. Esc(1–21)NH2 diastereomer Esc(1–21)-1C also exhibited activity against free-living and sessile forms of P. aeruginosa. Biondi et al. designed Esculatin (1–21)NH2 analogs with the incorporation of unnatural amino acid residue α-amino isobutyric acid for improving the activity of the parent peptide towards gram-positive bacterial strains. The designed analogs improved in helicity, activity against gram-positive bacterial strains with no induction of cytotoxic effects.

42Gopal et al. modified a previously reported peptide HPA3NT3 (FKRLKKLFKKIWNWK) by substituting Arg and Asparagine (Asn) with Lys and two Trps with Leu to synthesize analog FKKLKKLFKKILKLK-NH2 with an enhanced cationic character. Both the peptides were membranolytic and considerably active against several bacterial and fungal strains. The analog was more potent against gram-positive bacterial strains and less hemolytic (4.2%) compared to the parent peptide (71%) against hRBCs.

43Dinh et al. synthesized a doubly stapled peptide Ac-DS-14W based on Alanine (Ala)/Lys model sequence Ac-KXAKAXKKXAKAXWK-NH2. This peptide was designed to have two oct-4-enyl staples, which cross-linked residues at positions 2 and 6 and positions 9 and 13, respectively. For comparison, two more analogs of Ac-DS-14W, one singly stapled Ac-SS-14W and the other unstapled Ac-UM-14W were synthesized. Helical content of the peptides increased with the number of staplings in the peptides. Unstapled peptide was found to be inactive against all the tested microbes. Antimicrobial activity of the peptides increased with the number of staples, though doubly stapled peptides were found to have less activity against gram-negative bacteria K. pneumonia. Proteolytic resistance as well as cytotoxicity of the peptides increased with the number of staples in the peptides.

44Castelletto et al. designed a surfactant-like peptide with a single Arg residue Ala6-Arg (A6R) in which both the termini were capped/uncapped. Cap-A6R had a specific activity towards gram-positive Listeria monocytogenes while A6R was active against all the gram-positive and negative bacterial strains. The difference in activity was attributed to the selective interaction of the peptides with the membrane mimics..

45Dimeric temporin analog (TAd), all L modified temporin analog (TAL-L512) and all D temporin analog (TAD-L512) were synthesized. All the peptides showed antibacterial activity towards S. aureus. However, other than TAL-L512 all the other analogs were cytotoxic towards human keratinocytes. A synthetic analog of melittin named MeIP5, was shown to have very advanced pore forming ability in comparison to the parent peptide. The design involved the change of four positively charged amino acid residues in the nonpolar face of the amphipathic α-helix structure of melittin to hydrophobic amino acid residues. Reyes et al. studied the effect of trimethylation of the ε-amino groups of Lys at the selected positions of the antimicrobial hybrid peptide cecropin A-melittin KWKLFKKIGAVLKVL. Increase in Lys-(Me)3 residues, led to a decrease in both the antimicrobial activity against Leishmania, gram-positive bacteria like S. aureus and gram-negative bacteria like Acinetobactor baumannii. Membrane permeabilization and depolarization were the mechanism of action of the AMPs. The proteolytic stability of the peptides increased with the number of trimethylated Lys. Svenson et al. designed a library of tripeptides by employing Biphenylalanine (Bip) as the central residue flanked by Arg/Arg-like amino acids. Unnatural amino acids like phenylalanine (Phe) derivatives L-2-amino-3-(4-aminophenyl)- propanoic acid (App) and L-2-amino-3-(4-guanidinophenyl) propanoic acid (Gpp) were included to establish the influence of hydrophobic bulk in direct conjunction with the cationic charge on the antibacterial property of the peptides. Tripeptides containing two Gpp residues were most active followed by those containing one Arg and another Gpp residue. All the peptides showed low haemolytic activity. Hicks et al. used multiple repeats of two unnatural amino acid residues Tetrahydroisoquinolinecarboxylic acid (Tic) and Octahydroindolecarboxylic acid (Oic), spaced by two amino acid residues for constructing amphipathic α-helical AMPs. The peptides showed broad-spectrum antimicrobial activities against ESKAPE pathogens and haemolytic activities. Few of these designed AMPs showed activity in the in vivo mouse wound healing model. Kang et al. designed analogs of AMP Cbf-14 by the mutation of Lys and Leu residues with unnatural amino acid analogs Ornithine (Orn) and Nor-Leucine (Nle) respectively. An all D-amino acid residue containing analog was also developed. All the peptides had similar or better activity in comparison to Cbf-14 and negligible hemolysis in sheep RBCs. Peptides adopted helical conformation in the presence of membrane mimetic environments. One of the AMPs, Cbf-14–2 (Figure 7A) exhibited in vitro as well as in vivo activity against penicillin resistant bacteria, while retaining low toxicity against mammalian cells.

46Short lipopeptides were synthesized from tethering cationic tetrapeptide composed of one D-Phe, two L-2,4 diamino butyric acid and a L-Phe residue to fatty acids of different chain lengths. All the peptides were non-hemolytic and showed high activity towards gram-positive bacteria.. Chu-Kung et al. designed lauric acid derivates of three peptides AKK, SC4, and KAK. Lipidated AKK and SC4 showed improved antimicrobial potency in comparison to the non-lipidated analogs, in contrast to lipidated KAK, owing to the increased helical content of lipidated AKK with respect to KAK in the presence of microbial membrane mimetics. The cytotoxicity of lipidated AKK and KAK peptides was low in comparison to SC4 due to the ability of the later to indiscriminately adopt helical conformation in microbial and mammalian zwitterionic membrane mimic. This study concluded that lipidation could alter the antimicrobial potency and cytotoxicity of the peptides by altering the secondary structure of the peptides. (Figure 6C) Hu et al. synthesized several short cationic lipidated α-AA-peptides containing unnatural N-acylated-N-aminoethyl amino acid residues with broad-spectrum antimicrobial properties against clinically relevant bacterial and fungal strains. NB-123, NB-119–2 (Figure 7B), and NB-119–3 peptides exhibited better antimicrobial activity and selectivity in comparison to the clinical therapeutic pexiganan. The peptides were membranolytic in their activity which helped overcome the problem of the development of resistance against them. Short (RW)3 sequences with side chain lipidated terminal Lys residues had broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria. Both N and C-terminally lipidated peptides showed high activity against a broad range of pathogens including P. aeruginosa and A. baumannii, though the C terminal peptide had higher hemolytic activity. Zhong et al. designed fatty acid derivatives of AMP Anoplin (GLLKRIKTLL-NH2) and its D isomer. The fatty acid chains (4–16 carbon atoms long) were added to the side chains of the D-amino acid residues. The peptides showed excellent activity against a range of bacteria, especially the multidrug resistant ones, resistance to trypsin, serum, salts, pH environments and low tendency to develop antibacterial resistance. The lipidated AMPs showed membrane activity (outer/inner membrane permeability, membrane depolarization, deformation) in addition to possessing intracellular targets. Some of the peptides possessed in vivo antimicrobial potency, anti-inflammatory activity and endotoxin neutralization ability. Niu et al. synthesized a series of cationic lipo-γ-AA peptides with unsaturated lipid chains tethered to peptides composed of unnatural amino acid residues with positive side chains. The lipo-γ-AA peptides showed high broad-spectrum antimicrobial activities, low hemolytic activity and low resistance development abilities. Karlsson et al. designed cationic amphipathic 14-helical β-peptides formed from β amino acid residues with potent antifungal activity against C. albicans. Decamer β3Tyr-(Aminocyclohexane carboxylic acid (ACHC)-β3Valine (Val)- β3Lys)3 exhibited high potency and a moderate degree of hemolysis. Degrado and coworkers designed helical membranolytic peptides H-(β3-HAla-β3-HLys-β3-HVal)n-NH2 (where n = 4, 5) (Figure 7C) with high antimicrobial but low hemolytic potencies. AMPs containing E-vinylogous γ-amino acids in cationic (αγ)2 lipopeptides showed broad-spectrum antimicrobial property against several bacterial and fungal strains, when the side chains of the γ-amino acids were that of Ala, tyrosine (Tyr) and Phe. Self-assembled nanostructures played an important role in the activity and the hemolytic activity of the peptides.

Synthetic Cyclic Peptides:

47Cyclic peptides are found to have a superior affinity to the target receptors as compared to that of the linear form. Firstly, cyclization improves the proteolytic susceptibility of linear AMPs. Cyclization of peptides removes the reactive C and N-termini and acts as shielding components against the proteolytic enzymes. Secondly, cyclization improves binding the affinity of the AMPs for the microbial membranes. The flexibility of the linear AMPs, lead to an entropic penalty upon membrane binding. Cyclic AMPs with rigid structures do not incur entropic penalty upon membrane binding, which leads to its higher membrane binding affinity and hence activity. Figure 8 and Table 2 depicts some representative synthetic cyclic peptides.

48Synthetic cyclic peptide (Gly)6ccTP, an analog of the β-stranded AMP tachyplesin, showed salt tolerant activity against several microbial strains. (Gly)6ccTP contained eight mutated Gly residues instead of hydrophobic counterparts in the parent AMP and retained all the three disulfide bridges in the cyclic peptide backbone. Oh et al. studied two classes of amphiphilic cyclic cell-penetrating peptides (CPPs): 1) cyclic peptides containing Trp and Arg amino acid residues and 2) fatty acylated cyclic polyarginine peptides. Cyclic (R4W4) peptide had an enhanced activity in comparison to the linear R4W4 towards MRSA (Figure 8A). Antimicrobial potency of cyclo (R4W4) (2XMIC) with tetracyclin demonstrated was enhanced by 4-8 folds against MRSA and 2-8 folds against E. Coli with respect to the antibiotic alone. Among fatty acylated cyclic peptides, dodecanoyl (Figure 8B) and hexadecanoyl KR5 and dodecanoyl KR6 exhibited the highest potency against MRSA. The antimicrobial potency of the peptides was in the same order as their cell-penetrating abilities. In another study, cyclic AMPs with 6–12 amino residues were synthesized keeping in mind Ghadiri’s alternate D, L sequence design (Figure 8A) and cyclized via a xylene double thioether bridge connecting a pair of cys residues placed at both ends of a linear sequence to promote aggregation and serum stability. RH11 had good activity against P. aeruginosa including MDR clinical isolates, good serum stability and moderate hemolysis. These peptides were membranolytic in action.

49Nanotubes formed from cyclic peptides are another important class of antimicrobials. These nanotubes are stable against proteolytic degradation and easily formed on the charged membranes of bacteria. Unique supramolecular arrangements, made development of bacterial resistance against them. Ghadhiri et al. were the first to assemble cyclic peptide nanotubes by acidification of a pH-responsive octapeptide. Cyclic peptide assemblies from cyclic gamma or chiral β3 amino acid residues were much more stable owing to rigid backbone of the cyclic γ amino acid residues in comparison to the α amino acid residues. Antimicrobial activity of the CNPT against microbes is based on several factors like ring size, nature of constituent amino acid residues, nature and number of positively charged amino acid residues. Fernandez-Lopez et al. demonstrated that the antimicrobial activity of the cyclic peptides was way enhanced than their linear counterparts. Cyclic 8-mer AMPs showed better activity than the 6-mers. Antimicrobial and haemolytic activity remained the same on changing the chirality of the basic amino acids (Figure 8C). Motiei et al. studied membrane activity as well as in vitro activity of cationic cyclic D, L-α-glycopeptides bearing D-glucosamine (GlcNH2), D-galactose (Gal), or D-mannose (Man) glycosyl side chains. A membrane active amphiphilic parent peptide cyclic D, L-α-(WLWKSKSK) was modified to glycopeptides of the same charge but containing glycosyl side chains (Figure 8D). Glycosylation improved the activity against gram-positive bacterial strains including MSRA. The glycosylated peptides were protease resistant, had membrane permeation mode of action and cytotoxicity decided by the position and type of glycosyl residues.

Tryptophan, Proline, Histidine, Glycine Rich Synthetic Antimicrobial Peptides

50Learning from nature, several synthetic peptides have been developed which are rich in certain amino acid residues like Trp, Pro, His and Gly (Figure 9; Table 2). Due to its unique characteristics, several Trp rich short peptide antibiotics have been designed. A minimum of two Trp residues with a C terminal amidation was essential for the antimicrobial property. Additionally, about six amino acid residues were required for attaining maximum antimicrobial activity against gram-negative bacteria like E. coli or gram-positive bacteria like S. aureus. Increasing the number of Trp residues beyond six, marginally increased the activity while decreasing the number of Trp residues in hexa/heptapetides by mutation with Tyr residue led to significant inactivation of the peptide, especially against gram-negative bacterial strains.

51PAF26 (Acetyl-RKKWFW-NH2), a Trp rich antifungal hexapeptide was obtained from combinatorial chemistry, that is active against Penicillium italicum, Penicillium digitatum and Botrytis cinerea. Cyclic analog of the PAF26 was found to be active against gram-positive bacteria like S. aureus and S. sanguis and gram-negative bacteria like E. coli. It is also found to be active against pathogenic fungi like C. albicans. LfcinB4-9, RRWQWR was identified as the active antibacterial component of the LfcinB. Position of the Trp residues was as/more important than the number of Trp residues. Synthetic peptides KCM11(TWWRWW-NH2), KCM12(KWRWIW-NH2), KCM21(KWWWRW-NH2) and KCM22(WRWFIH-NH2) were identified from the positional screening of the synthetic peptide library and were shown to have activity against phytopathogenic bacteria Pectobacterium spp., Xanthomonas spp., and Pseudomonas spp.. LysH and Lys C were two cationic Trp rich peptides containing 7 and 15 amino acid residues respectively which were designed from the C terminal end of the human and egg while lysozyme. Both the peptides showed broad-spectrum antibacterial activity against gram-positive bacterial strains like B. subtilis, S. aureus, Streptococcus zooepidemicus and several gram-negative bacterial strains like E. coli, K. pneumonia, P. aeruginosa, Serratia marcescens. A rationally designed synthetic hexapeptide (RW)3 was highly active against bacterial strains like E. coli and S. aureus and pathogenic fungal strains like Fusarium solani and Fusarium oxysporum (F. oxysporum). Grain softness protein (MPLSWFFPRTWGKR-NH2) derived from the wheat grain exhibited antibacterial (E. coli, S. aureus) and antifungal activities (Colletotrichum graminicola, R. solani). GAK4AL, exhibited antibiotic activities against gram-negative bacterial strains like E. coli, K. pneumonia, Shigella dysenteriae, Salmonella typhimurium (S. typhimurium) and gram-positive bacterial strains like S. aureus, Staphylococcus epidermidis (S. epidermidis), P. aeruginosa, B. subtilis, Micrococcus luteus (M. luteus). PW2, a synthetic peptide isolated from the phage display library (HPLKQYWWRPSI) exhibited antifungal activity against Eimeriatenella, Eimeria acervulina, C. albicans, A. nidulans (Aspergillus nidulans).A synthetic linear and cyclic analog of the Indolicidin peptide CP-11(ILKKWPWWPWRRK-NH2) and cycloCP-11, with an increased positive charge and amphipathicity was shown to have enhanced activity against gram-negative bacteria. Both the peptides were found to have similar kind of structure and binding to membrane mimics, thus resulting in similar activity. However, the cyclic analog had much enhanced resistance to protease degradation in comparison to the linear analog. The carboxymethylated derivative CP-11C exhibited improved activity against gram-negative bacteria and C. albicans, while it retained activity against Staphylococci in comparison to Indolicidin. Hybrid peptides RN7-IN10 (Figure 9A), RN7-IN9, RN7- IN8, and RN7-IN6, based on two natural AMPs Indolicidin and Ranalexin, were shown to have broad-spectrum antimicrobial activity against S. aureus, MRSA, and E. coli. The hybrid AMPs were non-cytotoxic and non-hemolytic, and exhibited potent antibacterial activity against 30 different pneumococcal clinical isolates. Hybrid AMPs were more potent against K. Pneumoniae than standard drugs like erythromycin and ceftriaxone. A truncated 13 residue synthetic fragment (Puro A), containing the Trp rich domain of Puroindoline A was shown to exhibit native-like antimicrobial property and hence considered to be responsible for the bactericidal activity of Puroindoline A. Pasupuleti et al. designed two peptides GKHKNKGKKNGKHNGWK and KNKGKKNGKH from kininogen and added various length of Trp and Phe tags (Figure 9B). The antimicrobial potency of the AMPs increased with the length of the tags, which was related to the efficacy of lysis of the bacterial walls and to more pronounced bacterial lipopolysaccharide binding. The end tagged analogs were protease, salt, serum, and anionic macromolecular scavenger tolerant. Lee et al. designed a series of peptides based on the basic sequence (XWZX)n (n = 2–4, X: Lys or Arg, Z: Leu, Tyr, Val, or Gly). All the peptides showed low cytotoxicity and high antimicrobial properties against drug-susceptible and drug-resistant strains through membranolytic mechanisms. N terminal modified metallocenoyl {ferrocenoyl [FcC(O)-] or ruthenocenoyl [RcC(O)-]} derivatives of all L and diastereomeric WRWRW-NH2 were synthesized. Mostly all the derivatives were active against gram-positive bacterial strains like S. aureus, MRSA and B. subtilis. Most of the peptides were inactive against gram-negative strains and had limited hemolytic activity. Diasteromeric peptides had better activity than the all L peptides while FcC(O)- derivatives were more potent than the corresponding RcC(O)- derivatives. Four ultrashort Arg and Trp based peptides RW, WR, WRW and RWR were synthesized and covalently bound to two different trivalent scaffold molecules namely 1,3,5-tris(azidomethyl)- benzene and a 1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene using the copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC) reaction (Figure 9C ) to check the effect of preorganization of the AMPs on their antibacterial property. The AMPs were more active against the gram-positive compared to the gram-negative bacteria. Comparison of the activity with the Linear (RW)3-NH2 suggests that the presence of certain number of amino acids in the close vicinity is more important than their relative spatial orientation. High antimicrobial property was obtained by increasing the hydrophobic volume of the side chains of the amino acid residues. Hydrophobic chains such as Bip and 2.5.7 tri-tert-butyl Trp (Tbt) generated the most potent peptides when associated with either C terminal benzyl esters or amides (Hang et al., 2004). These peptides had much higher selectivity against gram-positive bacteria in comparison to the gram-negative bacteria. Applying Tbt amino acid residue instead of Trp in the RXR motif, highly active AMPs were obtained. An AMP RWRWRWA-(Bpa), with a photoactive group p-benzoyl-phenylalanine (Bpa) at the C- terminus was attached to a reverse osmosis (RO) membrane surface, upon UV radiation. Bacterial viability on the modified surfaces decreased by 55% with reduction of biofilm caused by P. aeruginosa. The viability of gram-positive bacteria E. faecalis on the peptide coated surface exhibited 29–40% bacterial inhibition. Hybrid Trp rich cationic peptides KU2 and KU3, generated from the fusion of two peptides KABT-AMP and Uperin 3.6 showed high antifungal potency against C. albicans. Though the peptides were non-hemolytic, they showed significant toxicity against human epithelial cell lines.

52Synthetic Pr-AMP PR-26, derived from the N terminus of the PR-39 exhibited higher activity towards enteric gram-negative bacteria. Pr-26 potentiated neutrophil phagocytosis of Salmonella choleraesuis and decreased the invasion of S. typhimurium into the intestinal epithelial cells. Pr-26 facilitated the pore forming AMPs like magainin A, thus potentiating the innate host defense against the gram-negative bacterial infections. Synthetic analogs of Pr-AMP Bac5, namely Bac(1–25) and Bac(1–31) exhibited excellent activity towards E. coli, while Bac(1–15) was inactive. Bac(1–25) and Bac(1–31) were shown to prevent protein synthesis in vitro and in vivo. PMAP-23 amphipathic α-helical peptide isolated from porcine was modified by incorporation of Trp residues at positions 10, 13 and 14 of the hydrophobic face of the peptide to generate improved antifungal activities. This increased the fungicidal and antitumor activities of the peptide.

53The His and Gly rich synthetic homodimer di-K19Hc designed from domain 1 of AMP Halocidin, was salt-tolerant and active against bacteria, yeast and filamentous fungi, such as C. albicans, C. neoformans (Cryotococcus neoformans), A. niger (Aspergillus niger), A. terreus (Aspergillus terreus) and F. oxysporum. One reported method to increase the salt tolerance of the synthetic AMPs was to replace the amino acid residues like His and Trp with bulky residues like β-naphthylalanine and β-(4,40 -Bip. However, these substitutions induced cytotoxicity and hemolytic activities in the peptides. Pep6 (FRLKFH), obtained from combinatorial chemistry, is a hexapeptide rich in Phe and His residues that is active against several plant pathogens like F. oxysporum f. sp. lycopersici, Rhizoctonia solani, Ceratocystis fagacearum and Pythium ultimum.

54N terminal tethering of fatty acids (palmitic/undecanoic) to the inactive diastereomers of Gly rich magainin (D4-magainin) or to very weakly active diastereomeric lytic peptide D-K5L7 conferred antifungal activity against Cryptococcus neoformans. Particularly D-K5L7-UA showed potency against all the different microbes like bacteria, fungi and yeast. AMP derivatives were synthesized by simultaneous introduction of positive charges as well as Pro residues in a typical antimicrobial peptide F5W-magainin 2 (MG2). The former and the later contributed to the increase in the antimicrobial activity and the reduction in the cytotoxicity of the peptides respectively, increasing the overall therapeutic index of the peptides. Results were sensitive to the position of the Pro substitution. The antimicrobial mechanism involved Lipopolysaccharide binding, membrane permeabilization, and DNA.

AMP Delivery Vehicles

55Another major concern in the commercialization of the AMPs as therapeutics arises from their modes of administration/delivery. It is now an accepted fact that the efficacy of any drug depends on its mode of delivery. In these lines, nanostructure based drug delivery systems have been found to be particularly promising. The nanostructured AMPs are more potent as they enhance the bio-availability of the drug, facilitate sustained release and improve retention of the AMPs in the bloodstream due to their enhanced retention and permeability effect. Poorer renal clearance of nanostructured AMPs leads to full exploitation of the materials in the blood stream due to enhanced retention and permeability effect (EPR effect). Nanoscale sized delivery vehicles improve the half-life and the stability of the AMPs. Table 3 summarizes some nanostructured AMPs.

56Certain small AMPs have the ability to self-assemble and form hydrogel (Figure 10). In the literature, there are reports of ultrashort AMPs, AMPs containing lipid chains and non-natural amino acids which have the ability to form macroscopic hydrogels. Hydrogels impregnated with the AMPs act as a protective shield and prevent the enzymatic, thermal and chemical degradation of the AMPs. These hydrogels may be constituted by synthetic polymers, natural polymers like collagen, silk, or peptides.

57MAXI, a twenty residue peptide, having two eight residue strands of alternating Val and Lys amino acids connected by a tetrapeptide sequence (-VDPPT-), could form a hydrogel composed of a network of interconnected fibrils rich in β-sheet, in DEMN cell culture at pH 7.4. The fibrils were composed of bilayers of intermolecularly H-bonded hairpins. This rigid hydrogel with β-hairpin conformation could kill both gram-positive and gram-negative bacteria through membranolytic mechanism of action In a separate study, Salick et al. designed a 20 residue amphiphilic β-hairpin peptide MARGI, which self-assembled into a fibrillar network resulting in a rigid hydrogel. This peptide contained two Arg groups at the 6th and 17th positions. The enhanced activity of MARGI over MAX1 against MRSA suggested that the inclusion of Arg might be critical for the enhanced action. Veiga et al. reported an optimized peptide containing six Arg residues, PEP6R from PEP8R, which folded into an amphiphilic β-hairpin conformation in buffer solution, rapidly self-assembling into a β-sheet rich fibrillar network, forming a hydrogel. The hydrogel exhibited distinct antibacterial efficiency toward E. coli and S. aureus via membranolytic mechanism. Also, the hydrogel was found to have a shear-thinning property and, thus could be used as a potential injectable material.

58CASP-K6, a cationic self-assembling AMP formed nano-fibrous hydrogel with membrane disrupting antimicrobial activity against P. aeruginosa colonies. CASP-K6 was a proteolytically stable and injectable hydrogel. Jiang et al. demonstrated that the antimicrobial activity of the hydrogels was related to their surface and rheological properties.

59AMP PAF26 formed hydrogel (Figure 10A) that exhibited antimicrobial activity against C. albicans, S. aureus, and E. coli through a membrane disruptive mechanism of action. Co-assembled hydrogels obtained from Fmoc-Phe and Fmoc -Leu amino acid derivatives showed activity against gram-positive bacteria through membrane disruptive process. Baral et al. reported a proteolytically stable N-Boc protected dipeptide (P1: Boc-AUDA-Phe-COOH) (Figure 10B) based injectable hydrogel, which showed excellent antibacterial activity against gram-negative bacteria (E. coli and P. aeruginosa), and biocompatibility with human red blood cells and human fibroblast cells. A series of five different peptide amphiphiles with a long fatty acyl chain of general chemical formula [H2N-(CH2)nCONH-Phe-CONHC12 (n = 1-5, C12 = dodecylamine)] (Figure 10C ) formed hydrogels at pH 6.6. Hydrogels with longer alkyl chain lengths were found to have higher membrane affinity and antibacterial activity against both gram-positive (B. subtilis and S. aureus) and gram-negative bacteria (E. coli). These hydrogels induced a small amount of hemolysis at their MIC for B. subtilis and E. coli and exhibited proteolytic resistance to enzymes proteinase K and chymotrypsin.

60Antimicrobial efficacy of AMP-NP systems depends on the rate, extent and the method of controlled release of the antimicrobials. Gold nanoparticle (Au-NP) based micro/nano structures are one of the most commonly used drug delivery systems owing to their biocompatibility with the mammalian systems due to their chemical inertness and stability. Gold nanoclusters (Au-NC) retain the biocompatibility of the AU-NP with an additional luminescent property that helps in bioimaging purposes. Antimicrobial activity of Au-NCs occur due to membrane disruption, DNA damage and generation of intracellular reactive oxygen species. Silver, oxides of metals such as titanium, copper, zinc and iron, are some of the excellent antimicrobial agents known. However, despite their excellent antimicrobial properties, many nanoparticle based antimicrobial agents have potential cytotoxicity that needs to be addressed. Immobilization of AMPs to metallic nanoparticles reduces cytotoxicity and improves the antimicrobial potency of the individual components synergistically. Some of the inherent drawbacks of AMPs, such as susceptibility to proteases and poor permeability across biological barriers, are also eliminated on conjugation with nanoparticles. Figure 11 schematically represents the synthesis of AMP-NP conjugates.

61Cell-penetrating peptide G3R6TAT was used as the stabilizer and reductant to produce colloid silver nanoparticles. Though the antimicrobial activity of the Ag-peptide was lower (against E. Coli, B. subtilis and C. albicans) compared to Ag-Citrate, Ag-SDS and Au@Ag, the Ag-peptide was much less hemolytic compared to the others. Pal et al. conjugated cationic antimicrobial peptide Odorranain-A-OA1 (VVKCSYRLGSPDSQCN) extracted from the skin of Chinese odorous frogs with AgNPs. AgNP-OA1 was more potent against E. coli and less cytotoxic in comparison to the AgNP alone. Maleki et al. reported the preparation of biocompatible antimicrobial SPION@gold core shell NPs based on the covalent immobilization of the AMP cecropin-melittin (CM). Antimicrobial activities of the AMP-NP conjugate against gram-positive (S. aureus) and gram-negative (E. Coli) bacteria were much better than the soluble AMPs. AMP-NPs demonstrated better destruction of the microbial membranes and less hemolytic activity compared to bare NPs. Pazos et al. designed PA nanofibers modified with functional groups that induced the formation of AgNPs over PA fibres. Peptide PA1 had an N-terminal aldehyde while the control peptide PA2 did not. Both the peptides formed nanofibres and on treating with Tollens reagent formed PA-AgNPs. Metallized PA nanofibers inhibited the growth of E. Coli inoculated in LB medium, whereas PA nanofibers did not. PA nanofibers were 30 times less toxic to the eukaryotic cells compared to the bacterial cells. Additionally, PA1-AgNPs formed antimicrobial gels with CaCl2. Otari et al. designed gold-nanoparticle alginate (Au-peptide-alginate) biohydrogel using a thermostable AMP nisin, effective against a variety of gram-positive bacteria. Au-peptide-alginate biohydrogel had significant antimicrobial activity against human bacterial pathogens S. aureus, B. cereus (Bacillus cereus), and E. faecalis, while the AuNP alginate did not.

Conclusion

62With the development of rapid resistance in microbes against standard antibiotics, the ability of the AMPs to invoke delayed resistance makes them an extremely potential therapeutic agent. Several AMPs in combination with conventional antibiotics have been shown to inhibit multiple drug-resistant strains which were resistant to the antibiotic alone, due to synergistic effect. Synthetic AMPs have been shown to have improved potency, diminished cytotoxicity, increased protease-resistance over the natural AMPs. A lot of potential therapeutic molecules can be developed by taking inspiration from the vast repertoire of AMPs that nature has to offer. Understanding the mechanisms of action of the AMPs will enable in the design of synthetic AMPs with improved specificity against specific microbial strains as well.

References 353

1.
Agerberth B. Lee J. Y. Bergman T. Carlquist M. Boman H. G. Mutt V. (1991 ). Amino Acid Sequence of PR-39. Isolation from Pig Intestine of a New Member of the Family of Proline-Arginine-Rich Antibacterial Peptides. Eur. J. Biochem. 202, 849–854.
Not in our library10.1111/j.1432-1033.1991.tb16442.x
2.
Akbari R. Hakemi Vala M. Pashaie F. Bevalian P. Hashemi A. PooshangBagheri K. (2019 ). Highly Synergistic Effects of Melittin with Conventional Antibiotics against Multidrug-Resistant Isolates of Acinetobacter Baumannii and. Pseudomonas aeruginosa. Microb. Drug Resist. 25, 193–202.
Not in our library10.1089/mdr.2018.0016
3.
Akpa E. Jacques P. Wathelet B. Paquot M. Fuchs R. Budzikiewicz H. (2001 ). Infuence of Culture Conditions on Lipopeptide Production by. Bacillus Subtilis. Appl. Biochem. Biotechnol. 91, 551–561.
Not in our library10.1385/abab:91-93:1-9:551
4.
Albada H. B. Prochnow P. Bobersky S. Bandow J. E. Metzler-Nolte N. (2014 ). Highly Active Antibacterial Ferrocenoylated or Ruthenocenoylated Arg-Trp Peptides Can Be Discovered by an L-To-D Substitution Scan. Chem. Sci. 5, 4453–4460.
Not in our library10.1039/c4sc01822b
5.
Albada H. B. Prochnow P. Bobersky S. Langklotz S. Schriek P. Bandow J. E. (2012 ). Tuning the Activity of a Short Arg-Trp Antimicrobial Peptide by Lipidation of a C- or N-Terminal Lysine Side-Chain. ACS Med. Chem. Lett. 3, 980–984.
Not in our library10.1021/ml300148v
6.
Albiol Matanic V. C. Castilla V. (2004 ). Antiviral Activity of Antimicrobial Cationic Peptides against Junin Virus and Herpes Simplex Virus. Int. J. Antimicrob. Agents 23, 382–389.
Not in our library10.1016/j.ijantimicag.2003.07.022
7.
Allahverdiyev A. M. Kon K. V. Abamor E. S. Bagirova M. Rafailovich M. (2011 ). Coping with Antibiotic Resistance: Combining Nanoparticles with Antibiotics and Other Antimicrobial Agents. Expert Rev. Anti-infect. Ther. 9, 1035–1052.
Not in our library10.1586/eri.11.121
8.
Andersen J. B. Koch B. Nielsen T. H. Sørensen D. Hansen M. Nybroe O. C. (2003 ). Surface Motility in Pseudomonas Sp. DSS73 Is Required for Efficient Biological Containment of the Root Pathogenic Micro Fungi Pythium Ultimum and Rhizoctonia solani. Microbiology 149, 37–46.
Not in our library10.1099/mic.0.25859-0
9.
Arima K. Kakinuma A. Tamura G. (1968 ). Surfactin, a Crystalline Peptide Lipid Surfactant Produced by Bacillus Subtilis: Isolation, Characterization and its Inhibition of Fibrin Clot Formation. Biothem. Biophys. Res. Commun. 31, 488–494.
Not in our library10.1016/0006-291x(68)90503-2
10.
Attoub S. Mechkarska M. Sonnevend A. Radosavljevic G. Jovanovic I. Lukic M. L. (2012 ). Esculentin-2CHa: a Host-Defense Peptide with Differential Cytotoxicity against Bacteria, Erythrocytes and Tumor Cells. Peptides. 39, 95–102.
Not in our library10.1016/j.peptides.2012.11.004
11.
Avrahami D. Shai Y. (2003 ). Bestowing Antifungal and Antibacterial Activities by Lipophilic Acid Conjugation to D, L-Amino Acid-Containing Antimicrobial Peptides: A Plausible Mode of Action. Biochemistry 42, 14946–14956.
Not in our library10.1021/bi035142v
12.
Azuma E. Choda N. Odaki M. Yano Y. Matsuzaki K. (2020 ). Improvement of Therapeutic index by the Combination of Enhanced Peptide Cationicity and Proline Introduction. ACS Infect. Dis. 6, 2271–2278.
Not in our library10.1021/acsinfecdis.0c00387
13.
Bagheri M. Nikolenko H. Arasteh S. Rezaei N. Behzadi M. Dathe M. (2020 ). Bacterial Aggregation Triggered by Fibril Forming Tryptophan-Rich Sequences: Effects of Peptide Side Chain and Membrane Phospholipids. ACS Appl. Mater. Inter. 12, 26852–26867.
Not in our library10.1021/acsami.0c04336
14.
Bals R. Wang X. Wu Z. Freeman T. Bafna V. Zasloff M. (1998 ). Human β-defensin 2 Is a Salt-Sensitive Peptide Antibiotic Expressed in Human Lung. J. Clin. Invest. 102, 874–880.
Not in our library10.1172/jci2410
15.
Baral A. Roy S. Ghosh S. Merino D. H. Hamley I. W. Banerjee A. (2016 ). A Peptide-Based Mechano-Sensitive, Proteolytically Stable Hydrogel with Remarkable Antibacterial Properties. Langmuir 32, 1836.
Not in our library10.1021/acs.langmuir.5b03789
16.
Bassarello C. Lazzaroni S. Bifulco G. Cantore P. L. Iacobellis N. S. (2004 ). Tolaasins A-E, Five New Lipodepsipeptides Produced by. Pseudomonas Tolaasii. J. Nat. Prod. 67, 811–816.
Not in our library10.1021/np0303557
17.
Baumann T. Kämpfer U. Schürch S. Schaller J. Largiadèr C. Nentwig W. (2010 ). Ctenidins: Antimicrobial Glycine-Rich Peptides from the Hemocytes of the Spider. Cupiennius Salei. Cel. Mol. Life Sci. 67, 2787–2798.
Not in our library10.1007/s00018-010-0364-0
18.
Bechinger B. Lohner K. (2006 ). Detergent-like Actions of Linear Amphipathic Cationic Antimicrobial Peptides. Biochim. Biophys. Acta 1758, 1529–1539.
Not in our library10.1016/j.bbamem.2006.07.001
19.
Biondi B. Casciaro B. Grazia A. D. Cappiello F. Luca V. Crisma M. (2017 ). Effects of Aib Residues Insertion on the Structural–Functional Properties of the Frog Skin-Derived Peptide esculentin-1a(1–21)NH2. Amino Acids 49, 139–150.
Not in our library10.1007/s00726-016-2341-x
20.
Blazyk J. Wiegand R. Klein J. Hammer J. Epand R. M. Epand R. F. (2001 ). A Novel Linear Amphipathic β-Sheet Cationic Antimicrobial Peptide with Enhanced Selectivity for Bacterial Lipids. J. Biol. Chem. 276 (2001), 27899–27906.
Not in our library10.1074/jbc.m102865200
21.
Blondelle S. E. PérezPayá E. Houghten R. A. (1996 ). Synthetic Combinatorial Libraries: Novel Discovery Strategy for Identification of Antimicrobial Agents. Antimicrob. Agents Chemother. 40, 1067–1071.
Not in our library10.1128/aac.40.5.1067
22.
Bohlman H. Apel K. (1991 ). Thionins. Annu. Rev. Plant Physiol. Plant Mol. Biol. 42, 227–240.
Not in our library10.1146/annurev.pp.42.060191.001303
23.
Bong D. T. Clark T. D. Granja J. R. Ghadiri M. R. (2001 ). Self-assembling Organic Nanotubes. Angew. Chem. Int. Ed. Engl. 40, 988–1011.
Not in our library10.1002/1521-3773(20010316)40:6<988::aid-anie9880>3.0.co;2-n
24.
Borro B. C. Nordström R. Malmsten M. (2020 ). Microgels and Hydrogels as Delivery Systems for Antimicrobial Peptides. Colloids Surf. B Biointerfaces. 187, 110835.
Not in our library10.1016/j.colsurfb.2020.110835
25.
Boxell A. Lee S. H. C. Jefferies R. Watt P. Hopkins R. Reid S. (2008 ). Pyrrhocoricinasa Potential Drug Delivery Vehicle for Cryptosporidium Parvum.. Exp. Parasitol. 119, 301–303.
Not in our library10.1016/j.exppara.2008.02.005
26.
Braff M. H. Gallo R. L. (2006 ). Antimicrobial Peptides: an Essential Component of the Skin Defensive Barrier. Curr. Top. Microbiol. Immunol. 306, 91–110.
Not in our library10.1007/3-540-29916-5_4
27.
Brockmann H. Scttmidt-Kastner G. (1955 ). Valinomycin I XXVII uber Antibiotica aus Actinomyceten. Chem. Ber. 88, 57–61.
Not in our library10.1002/cber.19550880111
28.
Brogden K. A. (2005 ). Antimicrobial Peptides: Pore Formers or Metabolic Inhibitors in Bacteria?. Nat. Rev. Microbiol. 3, 238–250.
Not in our library10.1038/nrmicro1098
29.
Brown K. L. Hancock R. E. W. (2006 ). Cationic Host Defense (Antimicrobial) Peptides. Curr. Opin. Immunol. 18, 24–30.
Not in our library10.1016/j.coi.2005.11.004
30.
Bulet P. Dimarcq J. L. Hetru C. Lagueux M. Charlet M. Hegy G. (1993 ). A Novel Inducible Antibacterial Peptide of Drosophila Carries an O-Glycosylated Substitution. J. Biol. Chem. 268, 14893–14897.
Not in our library10.1016/s0021-9258(18)82417-6
31.
Burr T. Matteson M. Smith C. Corral-Garcia M. Huang T-C. (1996 ). Effectiveness of Bacteria and Yeasts from Apple Orchards as Biological Control Agents of Apple Scab. Biol. Control. 6, 151–157.
Not in our library10.1006/bcon.1996.0019
32.
Burrows L. L. Stark M. Chan C. Glukhov E. Sinnadurai S. Deber C. M. (2006 ). Activity of Novel Non-amphipathic Cationic Antimicrobial Peptides against Candida Species. J. Antimicrob. Chemother. 57, 899–907.
Not in our library10.1093/jac/dkl056
33.
Cao F. Mei L. Zhu G. Song M. Zhang X. (2019 ). An Injectable Molecular Hydrogel Assembled by Antimicrobial Peptide PAF26 for Antimicrobial Application. RSC Adv. 9, 30803.
Not in our library10.1039/c9ra06130d
34.
Cappiello F. Grazia A. D. Segev-Zarko L-A. Scali S. Ferrera L. Galietta L. (2016 ). Esculentin-1a-derived Peptides Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a Plausible Mode of Action. Antimicrob. Agents Chemother. 60, 7252–7262.
Not in our library10.1128/aac.00904-16
35.
Carlsson A. Engström P. Palva E. T. Bennich H. (1991 ). Attacin, an Antibacterial Protein from Hyalophora Cecropia, Inhibits Synthesis of Outer Membrane Proteins in Escherichia coli by Interfering with Omp Gene Transcription. Infect. Immun. 59, 3040–3045.
Not in our library10.1128/iai.59.9.3040-3045.1991
36.
Carlsson A. Nyström T. de Cock H. Bennich H. (1998 ). Attacin—An Insect Immune Protein—Binds LPS and Triggers the Specific Inhibition of Bacterial Outer-Membrane Protein Synthesis. Microbiology 144, 2179–2188.
Not in our library10.1099/00221287-144-8-2179
37.
Small Cationic Peptides: Influence of Charge on Their Antimicrobial Activity · 2018
Not checked
38.
Casciaro B. Cappiello F. Loffredo M. R. Ghirga F. Mangoni M. L. (2020 ). The Potential of Frog Skin Peptides for Anti-infective Therapies: The Case of Esculentin-1a(1-21)NH2. Curr. Med. Chem. 27, 1405–1419.
Not in our library10.2174/0929867326666190722095408
39.
Casteels P. Ampe C. Jacobs F. Vaeck M. Tempst P. (1989 ). Apidaecins: Antibacterial Peptides from Honeybees. EMBO J. 8, 2387–2391.
Not in our library10.1002/j.1460-2075.1989.tb08368.x
40.
Casteels P. Ampe C. Riviere L. Van Damme J. Elicone C. Fleming M. (1990 ). Isolation and Characterization of Abaecin, a Major Antibacterial Response Peptide in the Honeybee (Apis mellifera). Eur. J. Biochem. 187, 381–386.
Not in our library10.1111/j.1432-1033.1990.tb15315.x
41.
Castelletto V. Barnes R. H. Karatzas K-A. Edwards-Gayle C. J. C. Greco F. Hamley I. W. (2018 ). Arginine Containing Surfactant-like Peptides: Interaction with Lipid Membranes and Antimicrobial Activity. Biomacromolecules 19, 2782–2794.
Not in our library10.1021/acs.biomac.8b00391
42.
Chan D. I. Prenner E. J. Vogel H. J. (2006 ). Tryptophan and Arginine-Rich Antimicrobial Peptides: Structures and Mechanisms of Action. Biochim. Biophys. Acta 1758, 1184–1202.
Not in our library10.1016/j.bbamem.2006.04.006
43.
Chapman R. Danial M. Koh M. L. Jolliffe K. A. Perrier S. (2012 ). Design and Properties of Functional Nanotubes from the Self-Assembly of Cyclic Peptide Templates. Chem. Soc. Rev. 41, 6023–6041.
Not in our library10.1039/c2cs35172b
44.
Chen J. Guan S. M. Sun W. Fu H. (2016 ). Melittin, the Major Pain Producing Substance of Bee Venom. Neurosci. Bull. 32, 265–272.
Not in our library10.1007/s12264-016-0024-y
45.
Chen Y. X. Vasil A. I. Rehaume L. Mant C. T. Burns J. L. Vasil M. L. (2006 ). Comparison of Biophysical and Biologic Properties of Alpha-Helical Enantiomeric Antimicrobial Peptides. Chem. Biol. Drug Des. 67, 162–173.
Not in our library10.1111/j.1747-0285.2006.00349.x
46.
Chesnokova L. S. Slepenkov S. V. Witt S. N. (2004 ). The Insect Antimicrobial Peptide, L-Pyrrhocoricin, Binds to and Stimulates the ATPase Activity of Both Wild-type and Lidless DnaK. FEBS Lett. 565, 65–69.
Not in our library10.1016/j.febslet.2004.03.075
47.
Choi J. H. Jang A. Y. Lin S. Lim S. Kim D. Park K. (2015 ). Melittin, a Honeybee Venom-Derived Antimicrobial Peptide, May Target Methicillin-Resistant Staphylococcus aureus. Mol. Med. Rep. 12, 6483–6490.
Not in our library10.3892/mmr.2015.4275
48.
Choi J. Moon E. (2009 ). Identification of Novel Bioactive Hexapeptides against Phytopathogenic Bacteria through Rapid Screening of a Synthetic Combinatorial Library. J. Microbiol. Biotechnol. 19, 792–802.
Not in our library10.4014/jmb.0809.497
49.
Chu-Kung A. F. Bozzelli K. N. Lockwood N. A. Haseman J. R. Mayo K. H. Tirrell M. V. (2004 ). Promotion of Peptide Antimicrobial Activity by Fatty Acid Conjugation Bioconjug. Chem. 15, 530–535.
Not in our library10.1021/bc0341573
50.
Cociancich S. Dupont A. Hegy G. Lanot R. Holder F. Hetru C. (1994 ). Novelinducible Antibacterial Peptides from a Hemipteran Insect, the Sap-Sucking Bug. Pyrrhocoris apterus. Biochem. J. 300, 567–575.
Not in our library10.1042/bj3000567
51.
Cole A. M. Kim Y. H. Tahk S. Hong T. Weis P. Waring A. J. (2001 ). Calcitermin, a Novel Antimicrobial Peptide Isolated from Human Airway Secretions. FEBS Lett. 504, 5–10.
Not in our library10.1016/s0014-5793(01)02731-4
52.
Cole A. M. Wang W. Waring A. J. Lehrer R. I. (2004 ). Retrocyclins: Using Past as Prologue. Curr. Protein Pept. Sci. 5, 373–381.
Not in our library10.2174/1389203043379657
53.
Colgrave M. L. Craik D. J. (2004 ). Thermal, Chemical, and Enzymatic Stability of the Cyclotide Kalata B1 the Importance of the Cyclic Cystine Knot. Biochemistry 43, 5965–5975.
Not in our library10.1021/bi049711q
54.
Conlon J. M. Mechkarska M. (2014 ). Host-defense Peptides with Therapeutic Potential from Skin Secretions of Frogs from the Family Pipidae. Pharmaceuticals 7, 58–77.
Not in our library10.3390/ph7010058
55.
Conlon J. M. Mechkarska M. Coquet L. Jouenne T. Leprince J. Vaudry H. (2011 ). Characterization of Antimicrobial Peptides in Skin Secretions from Discrete Populations of Lithobates Chiricahuensis (Ranidae) from central and Southern Arizona. Peptides 32, 664–669.
Not in our library10.1016/j.peptides.2011.01.018
56.
Craik D. J. (2010 ). Discovery and Applications of Plant Cyclotides. Toxicon 56, 1092–1102.
Not in our library10.1016/j.toxicon.2010.02.021
57.
Craik D. J. Daly N. L. Mulvenna J. Plan M. R. Trabi M. (2004 ). Discovery, Structure and Biological Activities of the Cyclotides. Curr. Protein Pept. Sci. 5, 297–315.
Not in our library10.2174/1389203043379512
58.
Da Silva A. Kawazoe U. Freitas F. F. T. Gatti M. S. V. Dolder H. Schumacher R. I. (2002 ). Avian Anticoccidial Activity of a Novel Membrane-Interactive Peptide Selected from Phage Display Libraries. Mol. Biochem. Parasitol. 120, 53–60.
Not in our library10.1016/s0166-6851(01)00439-x
59.
Daly N. L. Clark R. J. Plan M. R. Craik D. J. (2006 ). Kalata B8, a Novel Antiviral Circular Protein, Exhibits Conformational Flexibility in the Cystine Knot Motif. Biochem. J. 393, 619–626.
Not in our library10.1042/bj20051371
60.
Dartois V. Sanchez-Quesada J. Cabezas E. Chi E. Dubbelde C. Dunn C. (2005 ). Systemic Antibacterial Activity of Novel Synthetic Cyclic Peptides. Antimicrob. Agents Chemother. 49, 3302–3310.
Not in our library10.1128/aac.49.8.3302-3310.2005
61.
Diamond G. Beckloff N. Weinberg A. Kisich K. O. (2009 ). The Roles of Antimicrobial Peptides in Innate Host Defense. Curr. Pharm. Des. 15, 2377–2392.
Not in our library10.2174/138161209788682325
62.
Dimarcq J. L. Keppi E. Dunbar B. Lambert J. Reichhart J. M. Hoffmann D. (1988 ). Insect Immunity Purification and Characterization of a Family of Novel Inducible Antibacterial Proteins from Immunized Larvae of the Dipteran Phormia Terranovae and Complete Amino-Acid Sequence of the Predominant Member, Diptericin A. Eur. J. Biochem. 171, 17–22.
Not in our library10.1111/j.1432-1033.1988.tb13752.x
63.
Dinh T. T. T. Kim D-H. Luong H. X. Lee B-J. Kim Y-W. (2015 ). Antimicrobial Activity of Doubly-Stapled Alanine/lysine-Based Peptides. Bioorg. Med. Chem. Lett. 25, 4016–4019.
Not in our library10.1016/j.bmcl.2015.06.053
64.
Domachowske J. B. Bonville C. A. Dyer K. D. Rosenberg H. F. (1998 ). Evolution of Antiviral Activity in the Ribonuclease A Gene Superfamily: Evidence for a Specific Interaction between Eosinophil-Derived Neurotoxin (EDN/RNase 2) and Respiratory Syncytial Virus. Nucleic Acids Res. 26, 5327–5332.
Not in our library10.1093/nar/26.23.5327
65.
Dong N. Ma Q. Shan A. Lv Y. Hu W. Gu Y. (2012 ). Strand Length-dependent Antimicrobial Activity and Membrane-Active Mechanism of Arginine- and Valine-Rich β-hairpin-like Antimicrobial Peptides. Antimicrob. Agents Chemother. 56, 2994–3003.
Not in our library10.1128/aac.06327-11
66.
Dutta P. D. Das S. (2016 ). Mammalian Antimicrobial Peptides: Promising Therapeutic Targets against Infection and Chronic Inflammation. Curr. Top. Med. Chem. 16, 99–129.
Not in our library10.2174/1568026615666150703121819
67.
Eliassen L. T. Berge G. Sveinbjørnsson B. Svendsen J. S. Vorland L. H. Rekdal Ø. (2002 ). Evidence for a Direct Antitumor Mechanism of Action of Bovine Lactoferricin. Anticancer Res. 22, 2703–2710.
Not in our library
68.
Epand R. M. Epand R. F. Arnusch C. J. Papahadjopoulos-Sternberg B. Wang G. Shai Y. (2010 ). Lipid Clustering by Three Homologous Arginine-Rich Antimicrobial Peptides Is Insensitive to Amino Acid Arrangement and Induced Secondary Structure. Biochim. Biophys. Acta 1798, 1272–1280.
Not in our library10.1016/j.bbamem.2010.03.012
69.
Epand R. M. Vogel H. J. (1999 ). Diversity of Antimicrobial Peptides and Their Mechanisms of Action. Biochim. Biophys. Acta 1462, 11–28.
Not in our library10.1016/s0005-2736(99)00198-4
70.
Fahrner R. L. Dieckmann T. Harwig S. S. L. Lehrer R. I. Eisenberg D. Feigon J. (1996 ). Solution Structure of Protegrin-1, a Broad-Spectrum Antimicrobial Peptide from Porcine Leukocytes. Chem. Biol. 3, 543–550.
Not in our library10.1016/s1074-5521(96)90145-3
71.
Falla T. J. Hancock R. E. (1997 ). Improved Activity of a Synthetic Indolicidin Analog. Antimicrob. Agents Chemother. 41, 771–775.
Not in our library10.1128/aac.41.4.771
72.
Fehlbaum P. Bulet P. Michaut L. Lagueux M. Broekaert W. F. Hetru C. (1994 ). Insect Immunity. Septic Injury of Drosophila Induces the Synthesis of a Potent Antifungal Peptide with Sequence Homology to Plant Antifungal Peptides. J. Biol. Chem. 269, 33159–33163.
Not in our library10.1016/s0021-9258(20)30111-3
73.
Fernandez-Lopez S. Kim H. S. Choi E. C. Delgado M. Granja J. R. Khasanov A. (2001 ). Antibacterial Agents Based on the Cyclic D, L-Alpha-Peptide Architecture. Nature 412, 452–455.
Not in our library10.1038/35086601
74.
Fernandez-Reyes M. Diaz D. dela Torre B. G. Cabrales-Rico A. Valles-Miret M. Jimenez-Barbero J. (2010 ). Lysine N(epsilon)-Trimethylation, a Tool for Improving the Selectivity of Antimicrobial Peptides. J. Med. Chem. 53, 5587–5596.
Not in our library10.1021/jm100261r
75.
Fernández-Vidal M. Jayasinghe S. Ladokhin A. S. White S. H. (2007 ). Folding Amphipathic Helices into Membranes: Amphiphilicity Trumps Hydrophobicity. J. Mol. Biol. 2007 (370), 459–470.
Not in our library10.1016/j.jmb.2007.05.016
76.
Findlay B. Zhanel G. G. Schweizer F. (2010 ). Cationic Amphiphiles, a New Generation of Antimicrobials Inspired by the Natural Antimicrobial Peptide Scaffold. Antimicrob. Agents Chemother. 54, 4049–4058.
Not in our library10.1128/aac.00530-10
77.
Fleming A. (1992 ). On a Remarkable Bacteriolytic Element Found in Tissues and Secretions. Proc. R. Soc. 93, 306–317.
Not in our library10.1098/rspb.1922.0023
78.
Fletcher J. T. Finlay J. A. Callow M. E. Callow J. A. Ghadiri M. R. (2007 ). A Combinatorial Approach to the Discovery of Biocidal Six-Residue Cyclic D, L-α-Peptides against the Bacteria Methicillin-Resistant Staphylococcus aureus (MRSA) and E. coli and the Biofouling Algae Ulva Linza and. Navicula Perminuta. Chem.–Eur. J. 13, 4008–4013.
Not in our library10.1002/chem.200601583
79.
Florin T. Maracci C. Graf M. Karki P. Klepacki D. Berninghausen O. (2017 ). An Antimicrobial Peptide that Inhibits Translation by Trapping Release Factors on the Ribosome. Nat. Struct. Mol. Bio. 24, 752–757.
Not in our library10.1038/nsmb.3439
80.
Fontana R. Mendes M. A. deSouza B. M. Konno K. César L. M. Malaspina O. (2004 ). Jelleines: A Family of Antimicrobial Peptides from the Royal Jelly of Honeybees (Apis mellifera). Peptides 25, 919–928.
Not in our library10.1016/j.peptides.2004.03.016
81.
Fukuchi N. Isogai A. Nakayama J. Takayama S. Yamashita S. Suyama K. (1992 ). Structure and Stereochemistry of Three Phytotoxins, Syringomycin, Syringotoxin and Syringostatin, Produced by pseudomonas Syringae Pv. Syringae. J. Chem. Soc. Perkin Trans. 1, 1149–1157.
Not in our library10.1039/p19920001149
82.
Gagnon M. G. Roy R. N. Lomakin I. B. Florin T. Mankin A. S. Steitz T. A. (2016 ). Structures of Proline-Rich Peptides Bound to the Ribosome Reveal a Common Mechanism of Protein Synthesis Inhibition. Nucleic Acids Res. 44, 2439–2450.
Not in our library10.1093/nar/gkw018
83.
Gamberi T. Cavalieri D. Magherini F. Mangoni M. L. De Filippo C. Borro M. (2007 ). An Integrated Analysis of the Effects of Esculentin 1–21 on. Saccharomyces cerevisiae. Biochim. Biophys. Acta 1774, 688–700.
Not in our library10.1016/j.bbapap.2007.04.006
84.
Ganz T. (2001 ). Defensins in the Urinary Tract and Other Tissues. J. Infect. Dis. 183, 41–42.
Not in our library10.1086/318838
85.
Gao A. G. Hakimi S. M. Mittanck C. A. Wu Y. Woerner B. M. Stark D. M. (2000 ). Fungal Pathogen protection in Potato by Expression of a Plant Defensin Peptide. Nat. Biotechnol. 18, 1307–1310.
Not in our library10.1038/82436
86.
Gause G. F. Brazhnikova M. G. (1944 ). Gramicidin S and its Use in the Treatment of Infected Wounds. Nature 154, 703.
Not in our library10.1038/154703a0
87.
Gennaro R. Skerlavaj B. Romeo D. (1989 ). Purification, Composition, and Activity of Two Bactenecins, Antibacterial Peptides of Bovine Neutrophils. Infect. Immun. 57, 3142–3146.
Not in our library10.1128/iai.57.10.3142-3146.1989
88.
Gennaro R. Zanetti M. Benincasa M. Podda E. Miani M. (2002 ). Pro-rich Antimicrobial Peptides from Animals: Structure, Biological Functions and Mechanism of Action. Curr. Pharm. Des. 8, 763–778.
Not in our library10.2174/1381612023395394
89.
Ghadiri M. R. Granja J. R. Milligan R. A. McRee D. E. Khazanovich N. (1993 ). Self-assembling Organic Nanotubes Based on a Cyclic Peptide Architecture. Nature 366, 324–327.
Not in our library10.1038/366324a0
90.
Giacometti A. Cirioni O. Kamysz W. D’Amato G. Silvestri C. Prete Del. (2005 ). In Vitro activity and Killing Effect of Temporin A on Nosocomial Isolates of Enterococcus faecalis and Interactions with Clinically Used Antibiotics. J. Antimicrob. Chemother. 55, 272–274.
Not in our library10.1093/jac/dkh545
91.
Gifford J. L. Hunter H. N. Vogel H. J. (2005 ). Lactoferricin: a Lactoferrin-Derived Peptide with Antimicrobial, Antiviral, Antitumor and Immunological Properties. Cell Mol Life Sci. 62, 2588–2598.
Not in our library10.1007/s00018-005-5373-z
92.
Goldman M. J. Anderson G. M. Stolzenberg E. D. Kari U. P. Zasloff M. Wilson J. M. (1997 ). Human β-defensin-1 Is a Salt-Sensitive Antibiotic in Lung that Is Inactivated in Cystic Fibrosis. Cell 88, 553–560.
Not in our library10.1016/s0092-8674(00)81895-4
93.
Gomes P. S. Fernandes M. H. (2010 ). Defensins in the Oral Cavity: Distribution and Biological Role. J. Oral Pathol. Med. 39, 1–9.
Not in our library10.1111/j.1600-0714.2009.00832.x
94.
Gopal R. Na H. Seo C. H. Park Y. (2012 ). Antifungal Activity of (KW)n or (RW)n Peptide against Fusariumsolani and Fusarium Oxysporum. Int. J. Mol. Sci. 13, 15042–15053.
Not in our library10.3390/ijms131115042
95.
Gopal R. Park S-C. Ha K-J. Cho S. J. Kim S. W. Song P. I. (2009 ). Effect of Leucine and Lysine Substitution on the Antimicrobial Activity and Evaluation of the Mechanism of the HPA3NT3 Analog Peptide. J. Pept. Sci. 15, 589–594.
Not in our library10.1002/psc.1155
96.
Grgurina I. Bensaci M. Pocsfalvi G. Mannina L. Cruciani O. Fiore A. (2005 ). Novel Cyclic Lipodepsipeptide from Pseudomonas syringae Pv. Lachrymans Strain 508 and Syringopeptin Antimicrobial Activities. Antimicrob. Agents Chemother. 49, 5037–5045.
Not in our library10.1128/aac.49.12.5037-5045.2005
97.
Gudmundsson G. H. Agerbeth B. Odeberg J. Bergman T. Olsson B. Salcedo R. (1996 ). The Human Gene FALL-39 and Processing of the Cathelin Precursor to the Antibacterial Peptide LL-37 in Granulocytes. Eur. J. Biochem. 238, 325–332.
Not in our library10.1111/j.1432-1033.1996.0325z.x
98.
Habermann E. (1972 ). Bee and Wasp Venoms. Science 177, 314–322.
Not in our library10.1126/science.177.4046.314
99.
Hamann K. J. Gleich G. J. Checkel J. L. Loegering D. A. McCall J. W. Barker R. L. (1990 ). In Vitro killing of Microfilariae of Brugia Pahangi and Brugia malayi by Eosinophil Granule Proteins. J. Immunol. 144, 3166–3173.
Not in our library
100.
Hancock R. E. (1997 ). Peptide Antibiotics. Lancet 349, 418–422.
Not in our library10.1016/s0140-6736(97)80051-7
101.
Hancock R. E. W. Rozek A. (2002 ). Role of Membranes in the Activities of Antimicrobial Cationic Peptides. FEMS Microbiol. Lett. 206, 143–149.
Not in our library10.1111/j.1574-6968.2002.tb11000.x
102.
Hancock R. E. W. Sahl H-G. (2006 ). Antimicrobial and Host-Defense Peptides as New Anti-infective Therapeutic Strategies. Nat. Biotechnol. 24, 1551–1557.
Not in our library10.1038/nbt1267
103.
Hara S. Yamakawa M. (1995 ). A Novel Antibacterial Peptide Family Isolated from the Silkworm,. Bombyx mori.Biochem. J. 310, 651–656.
Not in our library10.1042/bj3100651
104.
Harder J. Bartels J. Christophers E. Schroeder J. M. (2001 ). Isolation and Characterization of Human Deta-Defensin-3, a Novel Human Inducible Peptide Antibiotic. J. Biol. Chem. 276, 5707–5713.
Not in our library10.1074/jbc.m008557200
105.
Harder J. Schroder J. M. (2002 ). RNase 7, a Novel Innate Immune Defense Antimicrobial Protein of Healthy Human Skin. J. Biol. Chem. 277, 46779–46784.
Not in our library10.1074/jbc.m207587200
106.
Harris F. Dennison S. R. Phoenix D. A. (2009 ). Anionic Antimicrobial Peptides from Eukaryotic Organisms. Curr. Protein Pept. Sci. 10, 585–606.
Not in our library10.2174/138920309789630589
107.
He R. Bonaventura I. D. Visini R. Gan B. H. Fu Y. Probst D. (2017 ). Design, crystal Structure and Atomic Force Microscopy Study of Thioether Ligated D, L-cyclic Antimicrobial Peptides Against Multidrug Resistant Pseudomonas aeruginosa. Chem. Sci. 8, 7464–7475.
Not in our library10.1039/c7sc01599b
108.
Heins S. D. Jimenez D. R. Manker D. C. Marrone P. G. McCoy R. J. Orjala J. E. (2000 ). Strain of bacillus for Controlling Plant Diseases and Corn Rootworm. US Patent 6060051 A.
Not in our library
109.
Heisey R. M. Huang J. Mishra S. K. Keller J. E. Miller J. R. Putnam A. R. (1988 ). Production of Valinomycin, an Insecticidal Antibiotic, by Streptomyces Griseus Var. Exipertum Var. Nov. J. Agric. Food Chem. 36, 1283–1286.
Not in our library10.1021/jf00084a039
110.
Hetru C. Troxler L. Hoffmann J. A. (2003 ). Drosophiola Melanogaster Antimicrobial Defense. J. Infect. Dis. 187, S327–S334.
Not in our library10.1086/374758
111.
Hicks R. P. Abercrombie J. J. Wong R. K. Leung K. P. (2013 ). Antimicrobial Peptides Containing Unnatural Amino Acid Exhibit Potent Bactericidal Activity against ESKAPE Pathogens. Bioorg. Med. Chem. 21, 205–214.
Not in our library10.1016/j.bmc.2012.10.039
112.
Hicks R. P. Bhonsle J. B. Venugopal D. Koser B. W. Magill A. J. (2007 ). De Novo design of Selective Antibiotic Peptides by Incorporation of Unnatural Amino Acids. J. Med. Chem. 2007 (50), 3026–3036.
Not in our library10.1021/jm061489v
113.
Hilchie A. L. Wuerth K. Hancock R. E. W. (2013 ). Immune Modulation by Multifaceted Cationic Host Defense (Antimicrobial) Peptides. Nat. Chem. Biol. 9, 761–768.
Not in our library10.1038/nchembio.1393
114.
Hoffknecht B. C. Albada H. B. Sturm M. Prochnow P. Bandow J. E. Metzler-Nolte N. (2015 ). Synthesis and Antibacterial Activity of Trivalent Ultrashort Arg-Trp-Based Antimicrobial Peptides (AMPs). Med. Chem. Commun. 6, 372–376.
Not in our library10.1039/c4md00327f
115.
Hoffmann J. A. Hetru C. (1992 ). Insect Defensins: Inducible Antibacterial Peptides. Immunol. Today 13, 411–415.
Not in our library10.1016/0167-5699(92)90092-l
116.
Hooper L. V. Stappenbeck T. S. Hong C. V. Gordon J. I. (2003 ). Angiogenins: A New Class of Microbicidal Proteins Involved in Innate Immunity. Nat. Immunol. 4, 269–273.
Not in our library10.1038/ni888
117.
Hou S. Zhou C. Liu Z. Young A. W. Shi Z. Ren D. (2009 ). Antimicrobial Dendrimer Active against Escherichia coli Biofilms. Bioorg. Med. Chem. Lett. 19, 5478–5481.
Not in our library10.1016/j.bmcl.2009.07.077
118.
Hu Y. Amin M. N. Padhee S. Wang R. E. Qiao Q. Bai G. (2012 ). Lipidated Peptidomimetics with Improved Antimicrobial Activity. ACS Med. Chem. Lett. 3, 683–686.
Not in our library10.1021/ml3001215
119.
Huang R. H. Xiang Y. Liu X. Z. Zhang Y. Hu Z. Wang D. C. (2002 ). Two Novel Antifungal Peptides Distinct with a Five-Disulfide Motif from the Bark of Eucommia Ulmoides Oliv. FEBS Lett. 521, 87–90.
Not in our library10.1016/s0014-5793(02)02829-6
120.
Huang R. H. Xiang Y. Tu G. Z. Zhang Y. Wang D. C. (2004 ). Solution Structure of Eucommia Antifungal Peptide a Novel Structural Model Distinct with a Five-Disulfide Motif. Biochemistry 43, 6005–6012.
Not in our library10.1021/bi036263y
121.
Huang T. Qian Y. Fu X. Huang S. Li Y. Zhou C. (2020 ). De Novo design of Triblock Amphiphilic Short Antimicrobial Peptides. ACS Appl. Polym. Mater. 9, 3988–3992.
Not in our library10.1021/acsapm.0c00640
122.
Huang X. Xie W. Gong Z. (2000 ). Characteristics and Antifungal Activity of a Chitin Binding Protein from. Ginkgo Biloba. FEBS Lett. 478, 123–126.
Not in our library10.1016/s0014-5793(00)01834-2
123.
Huang Y. C. Lin Y. M. Chang T. W. Wu S. J. Lee Y. S. Chang M. D. (2007 ). The Flexible and Clustered Lysine Residues of Human Ribonuclease 7 Are Critical for Membrane Permeability and Antimicrobial Activity. J. Biol. Chem. 2007 (282), 4626–4633.
Not in our library10.1074/jbc.m607321200
124.
Hultmark D. Engström A. Andersson K. Steiner H. Bennich H. Boman H. G. (1983 ). Insect Immunity. Attacins a Family of Antibacterial Proteins from Hyalophora Cecropia. EMBO J. 2, 571–576.
Not in our library10.1002/j.1460-2075.1983.tb01465.x
125.
Hunter H. N. Demcoe A. R. Jenssen H. Gutteberg T. J. Vogel H. J. (2005 ). Human Lactoferricin Is Partially Folded in Aqueous Solution and Is Better Stabilized in a Membrane Mimetic Solvent. Antimicrob. Agents Chemother. 49, 3387–3395.
Not in our library10.1128/aac.49.8.3387-3395.2005
126.
Hur G. H. Vickery C. R. Burkart M. D. (2012 ). Explorations of Catalytic Domains in Non-ribosomal Peptide Synthetase Enzymology. Nat. Prod. Rep. 29, 1074–1098.
Not in our library10.1039/c2np20025b
127.
Hussain S. Güzel Y. Pezzei C. Rainer M. Huck C. W. Bonn G. K. (2014 ). Solid-phase Extraction of Plant Thionins Employing Aluminum Silicate Based Extraction Columns. J. Sep. Sci. 37, 2200–2207.
Not in our library10.1002/jssc.201400385
128.
Hwang P. M. Zhou N. Shan X. Arrowsmith C. H. Vogel H. J. (1998 ). Three-dimensional Solution Structure of Lactoferricin B, an Antimicrobial Peptide Derived from Bovine Lactoferrin. Biochemistry 37, 4288–4298.
Not in our library10.1021/bi972323m
129.
Ikai K. Shiomi K. Takesako K. Mizutani S. Yamamoto J. Ogawa Y. (1991a ). Structures of Aureobasidins B to R. J. Antibiot. 44, 1187–1198.
Not in our library10.7164/antibiotics.44.1187
130.
Ikai K. Takesako K. Shiomi K. Moriguchi M. Umeda Y. Yamamoto J. (1991b ). Structure of Aureobasidin A. J. Antibiot. 44, 925–933.
Not in our library10.7164/antibiotics.44.925
131.
Ili´c N. Novkovi´c M. Guida F. Xhindoli D. Benincasa M. Tossi A. (2013 ). Selective Antimicrobial Activity and Mode of Action of Adepantins, Glycine-Rich Peptide Antibiotics Based on Anuran Antimicrobial Peptide Sequences. Biochim. Biophys. Acta 1828, 1004–1012.
Not in our library10.1016/j.bbamem.2012.11.017
132.
Imler J. L. Bulet P. (2005 ). Antimicrobial Peptides in Drosophila: Structures, Activities and Gene Regulation. Chem. Immunol. Allergy 86, 1–21.
Not in our library10.1159/000086648.104
133.
Ireland D. C. Clark R. J. Daly N. L. Craik D. J. (2010 ). Isolation, Sequencing, and Structure–Activity Relationships of Cyclotides. J. Nat. Prod. 73, 1610–1622.
Not in our library10.1021/np1000413
134.
Isono K. Suzuki S. (1979 ). The Polyoxins-Pyrimidine Nucleoside Peptide Antibiotics Inhibiting Fungal Cell-wall Biosynthesis. Heterocycles 13, 333–351.
Not in our library
135.
Jamasbi E. Lucky S. S. Li W. Hossain M. A. Gopalakrishnakone P. Separovic F. (2018 ). Effect of Dimerized Melittin on Gastric Cancer Cells and Antibacterial Activity. Amino Acids. 50, 1101–1110.
Not in our library10.1007/s00726-018-2587-6
136.
Jamasbi E. Mularski A. Separovic F. (2016 ). Model Membrane and Cell Studies of Antimicrobial Activity of Melittin Analogues. Curr. Top. Med. Chem. 16, 40–45.
Not in our library10.2174/1568026615666150703115919
137.
Jang W. S. Kim H. K. Lee K. Y. Kim S. A. Han Y. S. Lee I. H. (2006 ). Antifungal Activity of Synthetic Peptide Derived from Halocidin, Antimicrobial Peptide from the Tunicate. Halocynthia Aurantium. FEBS Lett. 580, 1490–1496.
Not in our library10.1016/j.febslet.2006.01.041
138.
Janiszewska J. Sowinska M. Rajnisz A. Solecka J. Lacka I. Milewski S. (2012 ). Novel Dendrimeric Lipopeptides with Antifungal Activity. Bioorg. Med. Chem. Lett. 22, 1388–1393.
Not in our library10.1016/j.bmcl.2011.12.051
139.
Javadpour M. M. Juban M. M. Lo W-C. J. Bishop S. M. Alberty J. B. Cowell S. M. (1996 ). De Novo antimicrobial Peptides with Low Mammalian Cell Toxicity. J. Med. Chem. 39, 3107–3113.
Not in our library10.1021/jm9509410
140.
Jenssen H. Hamill P. Hancock R. E. (2006 ). Peptide Antimicrobial Agents. Clin. Microbiol. Rev. 19, 491–511.
Not in our library10.1128/cmr.00056-05
141.
Jia F. Wang J. Peng J. Zhao P. Kong Z. Wang K. (2018 ). The In Vitro, In Vivo Antifungal Activity and the Action Mode of Jelleine-I against Candida Species. Amino Acids. 50, 229–239.
Not in our library10.1007/s00726-017-2507-1
142.
Jiang L. Xu D. Sellati T. J. Dong H. (2015 ). Self-assembly of Cationic Multidomain Peptide Hydrogels: Supramolecular Nanostructure and Rheological Properties Dictate Antimicrobial Activity. Nanoscale 7, 19160–19169.
Not in our library10.1039/c5nr05233e
143.
Jin Y. Hammer J. Pate M. Zhang Y. Zhu F. Zmuda E. (2005 ). Antimicrobial Activities and Structures of Two Linear Cationic Peptide Families with Various Amphipathic β-sheet and Alpha-Helical Potentials. Antimicrob. Agents Chemother. 49, 4957–4964.
Not in our library10.1128/aac.49.12.4957-4964.2005
144.
Jindal H. M. Le C. F. Yusof M. Y. Velayuthan R. D. Lee V. S. (2015 ). Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae. Plos ONE. 10 (6), e0128532.
Not in our library10.1371/journal.pone.0128532
145.
Jindal H. M. Zandi K. Ong K. C. Velayuthan R. D. Rasid S. M. Raju C. S. (2017 ). Mechanisms of Action and In Vivo Antibacterial Efficacy Assessment of Five Novel Hybrid Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae. PeerJ 5, e3887.
Not in our library10.7717/peerj.3887
146.
Jing W. Demcoe A. R. Vogel H. J. (2003 ). Conformation of a Bactericidal Domain of Puroindoline a: Structure and Mechanism of Action of a 13-Residue Antimicrobial Peptide. J. Bacteriol. 185, 4938–4947.
Not in our library10.1128/jb.185.16.4938-4947.2003
147.
Jonker A. M. Löwik D. W. P. M. van Hest V. J. C. M. (2012 ). Peptide- and Protein-Based Hydrogels. Chem. Mater. 24 (5), 759–773.
Not in our library10.1021/cm202640w
148.
Joo S. H. (2012 ). Cyclic Peptides as Therapeutic Agents and Biochemical Tools. Biomol. Ther. 20, 19–26.
Not in our library10.4062/biomolther.2012.20.1.019
149.
Juhaniewicz-Dębinśka J. Lasek R. Tymecka D. Burdach K. Bartosik D. Sęk S. (2020 ). Physicochemical and Biological Characterization of Novel Membrane-Active Cationic Lipopeptides with Antimicrobial Properties. Langmuir 36, 12900–12910.
Not in our library10.1021/acs.langmuir.0c02135
150.
Jung H. J. Park Y. Sung W. S. Suh B. K. Lee J. Hahm K. S. (2007 ). Fungicidal Effect of Pleurocidin by Membrane Active Mechanism and Design of Enantiomeric Analogue for Proteolytic Resistance. Biochim. Biophys. Acta 1768, 1400–1405.
Not in our library10.1016/j.bbamem.2007.02.024
151.
Kajimura Y. Kaneda M. (1997 ). Fusaricidins B, C and D, New Depsipeptide Antibiotics Produced by Bacillus Polymyxa KT-8: Isolation, Structure Elucidation and Biological Activity. J. Antibiot. 7, 50220–50228.
Not in our library
152.
Kang W. Liu H. Ma L. Wang M. Wei S. Sun P. (2017 ). Effective Antimicrobial Activity of a Peptide Mutant Cbf-14-2 against Penicillin-Resistant Bacteria Based on its Unnatural Amino Acids. Eur. J. Pharm. Sci. 105, 169–177.
Not in our library10.1016/j.ejps.2017.05.030
153.
DRAMP 2.0, an updated data repository of antimicrobial peptides · 2019
No notice
154.
Karlsson A. J. Pomerantz W. C. Weisblum B. Gellman S. H. Palecek S. P. (2006 ). Antifungal Activity from 14-helical β-peptides. J. Am. Chem. Soc. 128, 12630–12631.
Not in our library10.1021/ja064630y
155.
Karstad R. Isaksen G. Brandsdal B. O. Svendsen J. S. Svenson J. (2010 ). Unnatural Amino Acid Side Chains as S1, S1′, and S2′ Probes Yield Cationic Antimicrobial Peptides with Stability toward Chymotryptic Degradation. J. Med. Chem. 53, 5558–5566.
Not in our library10.1021/jm1006337
156.
Keppi E. Pugsley A. P. Lambert J. Wicker C. Dimarcq J. L. Hoffmann J. A. (1989 ). Mode of Action of Diptericin A. A Bactericidal Peptide Induced Hemolymph Phormia Terranovae Larvae. Insect Biochem. Physiol. 10, 229–239.
Not in our library10.1002/arch.940100306
157.
Kiba A. Saitoh H. Nishihara M. Omiya K. Yamamura S. (2003 ). C- Terminal Domain of a Hevein-like Protein from Wasabia Japonica Has Potent Antimicrobial Activity. Plant Cel Physiol. 44, 296–303.
Not in our library10.1093/pcp/pcg035
158.
Kim P. I. Ryu J. Kim Y. H. Chi Y.-T. (2010 ). Production of Biosurfactant Lipopeptides Iturin A, Fengycin and Surfactin A from Bacillus Subtilis CMB32 for Control of Colletotrichum Gloeosporioides. J. Microbiol. Biotechnol. 20, 138–145.
Not in our library10.4014/jmb.0905.05007
159.
Kolar S. S. N. Luca V. Baidouri H. Mannino G. McDermott A. M. Mangoni M. L. (2015 ). Esculentin-1a(1-21)NH2: a Frog Skin-Derived Peptide for Microbial Keratitis. Cell Mol. Life Sci. 72, 617–627.
Not in our library10.1007/s00018-014-1694-0
160.
Koo J. C. Lee S. Y. Chun H. J. Cheong Y. H. Choi J. S. Kawabata S. (1998 ). Lee, B.l., Cho, M. JTwo Hevein Homologs Isolated from the Seed of Pharbitis Nil L Exhibit Potent Antifungal Activity. Biochim. Biophys. Acta 1382, 80–90.
Not in our library10.1016/s0167-4838(97)00148-9
161.
Kragol G. Hoffmann R. Chattergoon M. A. Lovas S. Cudic M. Bulet P. (2002 ). Identification of Crucial Residues for the Antibacterial Activity of the Proline-Rich Peptide, Pyrrhocoricin. Eur. J. Biochem. 269, 4226–4237.
Not in our library10.1046/j.1432-1033.2002.03119.x
162.
Kragol G. Lovas S. Varadi G. Condie B. A. Hoffmann R. Otvos L. Jr. (2001 ). The Antibacterial Peptide Pyrrhocoricin Inhibits the ATPase Actions of DnaK and Prevents Chaperone-Assisted Protein Folding. Biochemistry 40, 3016–3026.
Not in our library10.1021/bi002656a
163.
Krause A. Neitz S. Magert H-J. Axel Schulz A. Wolf-Georg Forssmann W-G. Schulz-Knappe P. (2000 ). LEAP-1, a Novel Highly Disulfide-Bonded Human Peptide, Exhibits Antimicrobial Activity. FEBS Lett. 480, 147–150.
Not in our library10.1016/s0014-5793(00)01920-7
164.
Krause A. Sillard R. Kleemeier B. Klüver E. Maronde E. Conejo-García J. R. (2003 ). Isolation and Biochemical Characterization of LEAP-2, a Novel Blood Peptide Expressed in the Liver. Protein Sci. 12, 143–152.
Not in our library10.1110/ps.0213603
165.
Kul'ko A. B. Kisl O. V. Sadykova V. S. Mikhailov V. F. Vasilieva I. M. Shulenina L. V. (2016 ). Investigation of Thionins from Black Cumin (Nigella Sativa L.) Seeds Showing Cytotoxic, Regulatory and Antifungal Activity. Antibiot. Khimioter 61, 8–16.
Not in our library
166.
Lai R. Liu H. Hui Lee W. Zhang Y. (2002 ). An Anionic Antimicrobial Peptide from Toad Bombina Maxima. Biochem. Biophys. Res. Commun. 295, 796–799.
Not in our library10.1016/s0006-291x(02)00762-3
167.
Lakshminarayanan R. Liu S. Li J. Nandhakumar M. Aung T. T. Goh E. (2014 ). Synthetic Multivalent Antifungal Peptides Effective against Fungi. PLoS One. 9, e87730.
Not in our library10.1371/journal.pone.0087730
168.
Lalatsa A. Schatzlein A. G. Uchegbu I. F. (2014 ). Strategies to Deliver Peptide Drugs to the Brain. Mol. Pharm. 2014 (11), 1081–1093.
Not in our library10.1021/mp400680d
169.
Lavermicocca P. Sante Iacobellis N. Simmaco M. Graniti A. (1997 ). Biological Properties and Spectrum of Activity of Pseudomonas syringae Pv. Syringae Toxins. Physiol. Mol. Plant Pathol. 50, 129–140.
Not in our library10.1006/pmpp.1996.0078
170.
Lawyer C. Pai S. Watabe M. Borgia P. Mashimo T. Eagleton L. (1996 ). Antimicrobial Activity of a 13 Amino Acid Tryptophan-Rich Peptide Derived from a Putative Porcine Precursor Protein of a Novel Family of Antibacterial Peptides. FEBS Lett. 390, 95–98.
Not in our library10.1016/0014-5793(96)00637-0
171.
Leclère V. Béchet M. Adam A. Guez J.-S. Wathelet B. Ongena M. (2005 ). Mycosubtilin Overproduction by Bacillus Subtilis BBG100 Enhances the Organism’s Antagonistic and Biocontrol Activities. Appl. Environ. Microbiol. 71, 4577–4584.
Not in our library10.1128/aem.71.8.4577-4584.2005
172.
Lee D. G. Kim P. I. Park Y. Woo E. R. Choi J. S. Choi C. H. (2002 ). Design of Novel Peptide Analogs with Potent Fungicidal Activity, Based on PMAP-23 Antimicrobial Peptide Isolated from Porcine Myeloid. Biochem. Biophys. Res. Commun. 293, 231–238.
Not in our library10.1016/s0006-291x(02)00222-x
173.
Lee D. W. Kim B. S. (2015 ). Antimicrobial Cyclic Peptides for Plant Disease Control. Plant Pathol. J. 31, 1–11.
Not in our library10.5423/ppj.rw.08.2014.0074
174.
Anti-Inflammatory Applications of Melittin, a Major Component of Bee Venom: Detailed Mechanism of Action and Adverse Effects · 2016
No notice
175.
Lee J. Lee D. G. (2014 ). Melittin Triggers Apoptosis in Candida Albicans through the Reactive Oxygen Species-Mediated Mitochondria/caspase Dependent Pathway. FEMS Microbiol. Lett. 355, 36–42.
Not in our library10.1111/1574-6968.12450
176.
Lee M. Y. Park S.-C. Jung M. Shin M.-K. Kang H-L. Baik S-C. (2018 ). Cell-selectivity of Tryptophan and Tyrosine in Amphiphilic α-Helical Antimicrobial Peptides against Drug-Resistant Bacteria. Biochem. Biophys. Res. Commun. 505, 478–484.
Not in our library10.1016/j.bbrc.2018.09.095
177.
Lee S. H. Cho Y. E. Park S.-H. Balaraju K. Park J. W. Lee S. W. (2013 ). An Antibiotic Fusaricidin: a Cyclic Depsipeptide from Paenibacillus Polymyxa E681 Induces Systemic Resistance against Phytophthora Blight of Red-Pepper. Phytoparasitica 41, 49–58.
Not in our library10.1007/s12600-012-0263-z
178.
Leenders F. Stein T. H. Kablitz B. Franke P. Vater J. (1999 ). Rapid Typing of Bacillus Subtilis Strains by Their Sec- Ondary Metabolites Using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry of Intact Cells. Rapid Commun. Mass. Spectrom. 13, 943–949.
Not in our library10.1002/(sici)1097-0231(19990530)13:10<943::aid-rcm591>3.0.co;2-0
179.
Lehrer R. I. (2004 ). Primate Defensins. Nat. Rev. Microbiol. 2, 727–738.
Not in our library10.1038/nrmicro976
180.
Levashina E. A. Ohresser S. Bulet P. Reichhart J. M. Hetru C. Hoffmann J. A. (1995 ). Metchnikowin, a Novel Immune-Inducible Proline-Rich Peptide from Drosophila with Antibacterial and Antifungal Properties. Eur. J. Biochem. 233, 694–700.
Not in our library10.1111/j.1432-1033.1995.694_2.x
181.
Levashina E. A. Ohresser S. Lemaitre B. Imler J. L. (1998 ). Two Distinct Pathways Can Control Expression of the Gene Encoding the Drosophila Antimicrobial Peptide Metchnikowin. J. Mol. Biol. 278, 515–527.
Not in our library10.1006/jmbi.1998.1705
182.
Li S. S. Claeson P. (2003 ). Cys/Gly-rich Proteins with a Putative Single Chitin-Binding Domain from Oat (Avena Sativa) Seeds. Phytochemistry 63, 249–255.
Not in our library10.1016/s0031-9422(03)00116-x
183.
Lim T. H. Kwon S. Y. Seo H. W. Min B. S. Lim C. H. (2007 ). Antifungal Activity of Valinomycin, a Cyclo Depsipeptide from Streptomyces Padanus TH-04. Nat. Prod. Sci. 13, 144–147.
Not in our library
184.
Liu D. DeGrado W. F. (2001 ). De Novo design, Synthesis, and Characterization of Antimicrobial β-peptides. J. Am. Chem. Soc. 123, 7553–7559.
Not in our library10.1021/ja0107475
185.
Liu G. Kang D. Steiner H. (2000 ). Trichoplusia Ni Lebocin, an Inducible Immune Gene with a Downstream Insertion Element. Biochem. Biophys. Res. Commun. 269, 803–807.
Not in our library10.1006/bbrc.2000.2366
186.
Liu L. Xu K. Wang H. Tan J. Fan W. Venkatraman S. S. (2009 ). Self-assembled Cationic Peptide Nanoparticles as an Efficient Antimicrobial Agent. Nat. Nanotechnol. 4, 457–463.
Not in our library10.1038/nnano.2009.153
187.
Liu L. Yang J. Xie J. Luo Z. Jiang J. Yang Y. Y. (2013 ). The Potent Antimicrobial Properties of Cell Penetrating Peptide-Conjugated Silver Nanoparticles with Excellent Selectivity for Gram-Positive Bacteria over Erythrocytes. Nanoscale 5, 3834–3840.
Not in our library10.1039/c3nr34254a
188.
Liu Z. Brady A. Young A. Rasimick B. Chen K. Zhou C. (2007 ). Length Effects in Antimicrobial Peptides of the (RW)n Series. Antimicrob. Agents Chemother. 51, 597–603.
Not in our library10.1128/aac.00828-06
189.
Lopez-Garcia B. Gonzalez-Candelas L. Perez-Paya E. Marcos J. F. (2000 ). Identification and Characterization of a Hexapeptide with Activity against Phytopathogenic Fungi that Cause Postharvest Decay in Fruits. Mol. Plant-microbe Interact. 13, 837–846.
Not in our library10.1094/mpmi.2000.13.8.837
190.
Lopez-García B. Pérez-Payá E. Marcos J. F. (2002 ). Identification of Novel Hexapeptides Bioactive against Phytopathogenic Fungi through Screening of a Synthetic Peptide Combinatorial Library. Appl. Environ. Microbiol. 68, 2453–2460.,
Not in our library10.1128/aem.68.5.2453-2460.2002
191.
D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics · 2020
No notice
192.
Lum K. Y. Tay S. T. Le C. F. Lee V. S. Sabri N. H. Velayuthan R. D. (2015 ). Activity of Novel Synthetic Peptides against. Candida Albicans. Sci. Rep. 5, 9657–9669.
Not in our library10.1038/srep09657
193.
Maget-Dana R. Peypoux F. (1994 ). Iturins, a Special Class of Pore-Forming Lipopeptides: Biological and Physicochemical Properties. Toxicology 87, 151–174.
Not in our library10.1016/0300483x(94)90159-7
194.
Maleki H. Rai A. Pinto S. Evangalista M. Cardosa R. M. S. Paulo C. (2016 ). High Antimicrobial Activity and Low Human Cell Cytotoxicity of Core–Shell Magnetic Nanoparticles Functionalized with an Antimicrobial Peptide. ACS Appl. Mater. Inter. 8, 11366–11378.
Not in our library10.1021/acsami.6b03355
195.
Manchenko G. P. (1994 ). Lysozyme. Handbook of Detection of Enzymes on Electrophoretic Gels. Boca Raton, Fla: CRC Press, 223.
Not in our library
196.
Mangoni M. L. (2006 ). Temporins, Anti-infective Peptides with Expanding Properties. Cell. Mol. Life Sci. 63, 1060–1069.
Not in our library10.1007/s00018-005-5536-y
197.
Mangoni M. L. Fiocco D. Mignogna G. Barra D. Simmaco M. (2003 ). Functional Characterisation of the 1–18 Fragment of Esculentin-1b, an Antimicrobial Peptide from. Rana esculenta. Peptides 24, 1771–1777.
Not in our library10.1016/j.peptides.2003.07.029
198.
Mangoni M. L. Marcellini H. G. L. Simmaco M. (2007 ). Biological Characterization and Modes of Action of Temporins and Bombinins H, Multiple Forms of Short and Mildly Cationic Anti-microbial Peptides from Amphibian Skin. J. Pept. Sci. 13, 603–613.
Not in our library10.1002/psc.853
199.
Mangoni M. L. Papo N. Mignogna G. Andreu D. Shai Y. Barra D. (2003b ). Ranacyclins, a New Family of Short Cyclic Antimicrobial Peptides: Biological Function, Mode of Action, and Parameters Involved in Target Specificity. Biochemistry 42, 14023–14035.
Not in our library10.1021/bi034521l
200.
Mangoni M. L. Papo N. Saugar J. M. Barra D. Shai Y. Simmaco M. (2006 ). Effect of Natural L- to D-Amino Acid Conversion on the Organization, Membrane Binding, and Biological Function of the Antimicrobial Peptides Bombinins H. Biochemistry 45, 4266–4276.
Not in our library10.1021/bi052150y
201.
Mangoni M. L. Saugar J. M. Dellisanti M. Barra D. Simmaco M. Rivas L. (2005 ). Temporins, Small Antimicrobial Peptides with Leishmanicidal Activity. J. Biol. Chem. 280, 984–990.
Not in our library10.1074/jbc.m410795200
202.
Mantyla T. Sirola H. Kansanen E. Korjamo T. Lankinen H. LAppalainen K. (2005 ). Effect of Temporin A Modifications on its Cytotoxicity and Antimicrobial Activity. APMIS 113, 497–505.
Not in our library10.1111/j.1600-0463.2005.apm_107.x
203.
Mao C. Mohanraj G. Kandiyote N. S. Kasher R. Arnusch C. J. (2018 ). UV Mediated Attachment of Short Arginine-Tryptophan Antimicrobial Peptides on Reverse Osmosis Membrane Surfaces Inhibit Pseudomonas aeruginosa Biofilm. Desalination 431, 73–79.
Not in our library10.1016/j.desal.2017.12.027
204.
Mardirossian M. Barriere Q. Timchenko T. Muller C. Pacor S. Margaert P. (2018 ). Fragments of the Nonlytic Proline-Rich Antimicrobial Peptide Bac5 Kill Escherichia coli Cells by Inhibiting Protein Synthesis. Antimicrob. Agents Chemother. 62, e00534–18.
Not in our library10.1128/aac.00534-18
205.
Mathur S. Singh R. (2005 ). Antibiotic Resistance in Food Lactic Acid Bacteria—A Review. Int. J. Food Microbiol. 105, 281–295.
Not in our library10.1016/j.ijfoodmicro.2005.03.008
206.
McCloskey A. P. Draper E. R. Gilmore B. F. Laverty G. (2017 ). Ultrashort Self-Assembling Fmoc-Peptide Gelators for Anti-infective Biomaterial Applications. J. Pept. Sci. 23, 131–140.
Not in our library10.1002/psc.2951
207.
McManus A. M. Otvos L. Jr. Hoffmann R. Craik D. J. (1999 ). Conformational Studies by NMR of the Antimicrobial Peptide, Drosocin, and its Non-glycosylated Derivative: Effects of Glycosylation on Solution Conformation. Biochemistry 38, 705–714.
Not in our library10.1021/bi981956d
208.
Melchionna M. Styan K. Marchesan S. (2016 ). The Unexpected Advantages of Using D- Amino Acids for Peptide Self-Assembly into Nanostructured Hydrogels for Medicine. Curr. Top. Med. Chem. 16, 2009–2018.
Not in our library10.2174/1568026616999160212120302
209.
Tryptophan-Rich and Proline-Rich Antimicrobial Peptides · 2018
No notice
210.
Miyoshi N. Isogai E. Hiramatsu K. Sasaki T. (2017 ). Activity of Tick Antimicrobial Peptide from Ixodes Persulcatus (Persulcatusin) against Cell Membranes of Drug-Resistant. Staphylococcus aureus. J. Antibiot. 70, 142–146.
Not in our library10.1038/ja.2016.101
211.
Miyoshi N. Saito T. Ohmura T. Kuroda K. Suita K. Ihara K. (2016 ). Functional Structure and Antimicrobial Activity of Persulcatusin, an Antimicrobial Peptide from the Hard Tick. Ixodes Persulcatus. Parasites Vectors 9, 85.
Not in our library10.1186/s13071-016-1360-5
212.
Mizuhara N. Kuroda M. Ogita A. Tanaka T. Usuki Y. Fujita K.-I. (2011 ). Antifungal Thiopeptide Cyclothiazomycin B1 Exhibits Growth Inhibition Accompanying Morphological Changes via Binding to Fungal Cell wall Chitin. Bioorg. Med. Chem. 19, 5300–5310.
Not in our library10.1016/j.bmc.2011.08.010
213.
Mookherjee N. Anderson M. A. Haagsman H. P. Davidson D. J. (2020 ). Antimicrobial Host Defence Peptides: Functions and Clinical Potential. Nat. Rev. Drug Discov. 19, 311–332.
Not in our library10.1038/s41573-019-0058-8
214.
Moorcroft S. C. T. Roach L. Jayne D. G. Ong Z. Y. Evans S. D. (2020 ). Nanoparticle-loaded Hydrogel for the Light-Activated Release and Photothermal Enhancement of Antimicrobial Peptides. ACS Appl. Mater. Inter. 12, 24544–24554.
Not in our library10.1021/acsami.9b22587
215.
Moore A. J. Beazley W. D. Bibby M. C. Devine D. A. (1996 ). Antimicrobial Activity of Cecropins. J. Antimicrobiol. Chemother. 37, 1077–1089.
Not in our library10.1093/jac/37.6.1077
216.
Motiei L. Rahimipour S. Thayer D. A. Wong C. H. Ghadiri M. R. (2009 ). Antibacterial Cyclic D, L-α-Glycopeptides. Chem. Commun. 49, 3693–3695.
Not in our library10.1039/b902455g
217.
Muñoz A. López-García B. Marcos J. F. (2006 ). Studies on the Mode of Action of the Antifungal Hexapeptide PAF26. Antimicrob. Agents Chemother. 50, 3847–3855.
Not in our library10.1128/aac.00650-06
218.
Murakami M. Ohtake T. Dorschner R. A. Schittek B. Garbe C. Gallo R. L. (2002 ). Cathelicidin Antimicrobial Peptide Expression in Sweat, an Innate Defense System for the Skin. J. Invest. Dermatol. 119, 1090–1095.
Not in our library10.1046/j.1523-1747.2002.19507.x
219.
Murray T. Leighton F. C. Seddon B. (1986 ). Inhibition of Fungal Spore Germination by Gramicidin S and its Potential Use as a Biocontrol against Fungal Plant Pathogens. Lett. Appl. Microbiol. 3, 5–7.
Not in our library10.1111/j.1472-765x.1986.tb01534.x
220.
Mygind P. H. Fischer R. L. Schnorr K. M. Hansen M. T. Sonksen C. P. Ludvigsen S. (2005 ). Plectasin Is a Peptide Antibiotic with Therapeutic Potential from a Saprophytic Fungus. Nature 437, 975–980.
Not in our library10.1038/nature04051
221.
Diversity, evolution and medical applications of insect antimicrobial peptides · 2016
No notice
222.
Nandi N. Gayen K. Ghosh S. Bhunia D. Kirkham S. Sen S. K. (2017 ). Amphiphilic Peptide-Based Supramolecular, Non-cytotoxic, Stimuli-Responsive Hydrogels with Antibacterial Activity. Biomacromolecules 18, 3621–3629.
Not in our library10.1021/acs.biomac.7b01006
223.
Nawrot R. Barylski J. Nowicki G. Broniarczyk J. Buchwald W. Goździcka-Józefiak A. (2014 ). Plant Antimicrobial Peptides. Folia Microbiol. 59, 181–196.
Not in our library10.1007/s12223-013-0280-4
224.
Ngai P. H. Ng T. B. (2005 ). Phaseococcin, an Antifungal Protein with Antiproliferative and Anti-HIV-1 Reverse Transcriptase Activities from Small Scarlet Runner Beans. Biochem. Cel Biol. 83, 212–220.
Not in our library10.1139/o05-037
225.
Nicolas P. (2009 ). Multifunctional Host Defense Peptides: Intracellular Targeting Antimicrobial Peptides. FEBS J. 276, 6483–6496.
Not in our library10.1111/j.1742-4658.2009.07359.x
226.
Nielsen T. H. Christophersen C. Anthoni U. Sorensen J. (1999 ). Viscosinamide, a New Cyclic Depsipeptide with Surfactant and Antifungal Properties Produced by Pseudomonas Fluorescens DR54. J. Appl. Microbiol. 87, 80–90.
Not in our library10.1046/j.1365-2672.1999.00798.x
227.
Nielsen T. H. Sorensen D. Tobiasen C. Andersen J. B. Christophersen C. Givskov M. Sorensen J. (2002 ). Antibiotic and Biosurfactant Properties of Cyclic Lipopeptides Produced by Fluorescent Pseudomonas Spp. from the Sugar Beet RhizoSphere. Appl. Environ. Microbiol. 68, 3416–3423.
Not in our library10.1128/aem.68.7.3416-3423.2002
228.
Nielsen T. H. Sorensen J. (2003 ). Production of Cyclic Lipo- Peptides by Pseudomonas Uorescens Strains in Bulk Soil and in the Sugar Beet Rhizosphere. Appl. Environ. Microbiol. 69, 861–868.
Not in our library10.1128/aem.69.2.861-868.2003
229.
Nielsen T. H. Thrane C. Christophersen C. Anthoni U. Sørensen J. (2000 ). Structure, Production Characteristics and Fungal Antagonism of Tensin—A New Antifungal Cyclic Lipopeptide from Pseudomonas Fluorescens Strain 96.578. J. Appl. Microbiol. 89, 992–1001.
Not in our library10.1046/j.1365-2672.2000.01201.x
230.
Nikawa N. Fukushima H. Makihira S. Hamada T. Samaranayake L. P. (2004 ). Fungicidal Effect of Three New Synthetic Cationic Peptides against. Candida Albicans. Oral Dis. 10, 221–228.
Not in our library10.1111/j.1601-0825.2004.01010.x
231.
Niu Y. Padhee S. Wu H. Bai G. Qiao Q. Hu Y. (2012 ). Lipo-γ-AA Peptides as a New Class of Potent and Broad-Spectrum Antimicrobial Agents. J. Med. Chem. 55, 4003–4009.
Not in our library10.1021/jm300274p
232.
Oh D. Sun J. Shirazi A. N. LaPlante K. L. Rowley D. C. Parang K. (2014 ). Activities of Amphiphilic Cyclic Cell-Penetrating Peptides against Multidrug-Resistant Pathogens. Mol. Pharm. 11, 3528–3536.
Not in our library10.1021/mp5003027
233.
Ongena M. Jacques P. Tour Y. Destain J. Jabrane A. Thonart P. (2005 ). Involvement of Fengycin-type Lipopeptides in the Multifaceted Biocontrol Potential of. Bacillus Subtilis. Appl. Microbiol. Biotechnol. 69, 29–38.
Not in our library10.1007/s00253-005-1940-3
234.
Oppenheim F. G. Xu T. McMillian F. M. Levitz S. M. Diamond R. D. Offner G. D. (1988 ). Histatins, a Novel Family of Histidine-Rich Proteins in Human Parotid Secretion. Isolation, Characterization, Primary Structure, and Fungistatic Effects on. Candida Albicans. J. Biol. Chem. 263, 7472–7477.
Not in our library10.1016/s0021-9258(18)68522-9
235.
Osada Y. Kajiwara K. ed. (2001 ). Gels Hand Book, assoc. ed. Fushimi T. Hirasa O. Hirokawa Y. Matsunaga T. Shimomura T. Wang L., Vols. 1–3, Academic Press, San Diego.
Not in our library
236.
Otari S. V. Patel S. K. S. Jeong J. H. Lee J. H. Lee J. K. (2016 ). A green Chemistry Approach for Synthesizing Thermostable Antimicrobial Peptide-Coated Gold Nanoparticles Immobilized in an Alginate Biohydrogel. RSC Adv. 6, 86808–86816.
Not in our library10.1039/c6ra14688k
237.
Ouyang L. Xu X. Freed S. Gao Y. Yu J. Wang S. (2015 ). Cecropins from Plutella Xylostella and Their Interaction with Metarhizium Anisopliae. PLoS ONE 10, e0142451.
Not in our library10.1371/journal.pone.0142451
238.
Pal I. Bhattacharyya D. Kar R. K. Zarena D. Bhunia A. Atreya H. S. (2019 ). A Peptide-Nanoparticle System with Improved Efficacy against Multidrug Resistant Bacteria. Sci. Rep. 14, 4485.
Not in our library10.1038/s41598-019-41005-7
239.
Pal I. Brahmkhatri V. P. Bera S. Bhattacharyya D. Quirishi Y. Bhunia A. (2016 ). Enhanced Stability and Activity of an Antimicrobial Peptide in Conjugation with Silver Nanoparticle. J. Colloid Interf. Sci. 483, 385–393.
Not in our library10.1016/j.jcis.2016.08.043
240.
Pandit G. Biswas K. Ghosh S. Debnath S. Bidkar A. P. Satpati P. (2020 ). Rationally Designed Antimicrobial Peptides: Insight into the Mechanism of Eleven Residue Peptides against Microbial Infections. Biochim. Biophys. Acta Biomembr. 1862, 183177–183193.
Not in our library10.1016/j.bbamem.2020.183177
241.
Pandit G. Ilyas H. Ghosh S. Bidkar A. P. Mohid Sk. A. Bhunia A. (2018 ). Insights into the Mechanism of Antimicrobial Activity of Seven- Residue Peptides. J. Med. Chem. 61, 7614–7629.
Not in our library10.1021/acs.jmedchem.8b00353
242.
Pandit G. Chowdhury N. Mohid S. A. Bidkar A. P. Bhunia A. Chatterjee A. (2021 ). Effect of Secondary Structure and Side Chain Length of Hydrophobic Amino Acid Residues on the Antimicrobial Activity and Toxicity of 14-Residue-Long de novo AMPs. ChemMedChem. 16, 355–367.
Not in our library10.1002/cmdc.202000550
243.
Papo N. Shai Y. (2003 ). Can We Predict Biological Activity of Antimicrobial Peptides from Their Interactions with Model Phospholipid Membranes?. Peptides 24, 1693–1703.
Not in our library10.1016/j.peptides.2003.09.013
244.
Park C. B. Kim H. S. Kim S. C. (1998 ). Mechanism of Action of the Antimicrobial Peptide Buforin II: Buforin II Kills Microorganisms by Penetrating the Cell Membrane and Inhibiting Cellular Functions. Biochem. Biophys. Res. Commun. 244, 253–257.
Not in our library10.1006/bbrc.1998.8159
245.
Park C. B. Kim M. S. Kim S. C. (1996 ). A Novel Antimicrobial Peptide from Bufo bufo Gargarizans. Biochem. Biophys. Res. Comm. 218, 408–413.
Not in our library10.1006/bbrc.1996.0071
246.
Park C. B. Yi K.-S. Matsuzaki K. Kim M. S. Kim S. C. (2000 ). Structure–activity Analysis of Buforin II, a Histone H2A-Derived Antimicrobial Peptide: The Proline Hinge Is Responsible for the Cell-Penetrating Ability of Buforin II. PNAS 97, 8245–5820.
Not in our library10.1073/pnas.150518097
247.
Park C. H. Valore E. V. Waring A. J. Ganz T. (2001a ). Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J. Biol. Chem. 276, 7806–7801.
Not in our library10.1074/jbc.m008922200
248.
Park C. N. Lee J. M. Lee D. Kim B. S. (2008 ). Antifungal Activity of Valinomycin, a Peptide Antibiotic Produced by Streptomyces Sp. Strain M10 Antagonistic Botrytis Cinerea. J. Microbiol. Biotechnol. 18, 880–884.
Not in our library
249.
Park S. Park S. H. Ahna H. C. Kimb S. Kimb S. S. Lee B. J. (2001 ). Structural Study of Novel Antimicrobial Peptides, Nigrocins, Isolated from. Rana nigromaculata. FEBS Lett. 507, 95–100.
Not in our library10.1016/s0014-5793(01)02956-8
250.
Pasupuleti M. Chalupka A. Mörgelin M. Schmidtchen A. Malmsten M. (2009 ). Tryptophan End-Tagging of Antimicrobial Peptides for Increased Potency against Pseudomonas aeruginosa. Biochim. Biophys. Acta 1790, 800–808.
Not in our library10.1016/j.bbagen.2009.03.029
251.
Patocka J. Nepovimova E. Klimova B. Wu Q. Kuca K. (2019 ). Antimicrobial Peptides: Amphibian Host Defense Peptides. Curr. Med. Chem. 26, 5924–5946.
Not in our library10.2174/0929867325666180713125314
252.
Pazos E. Sleep E. Pérez C. M. R. Lee S. S. Tantakitti F. Stupp S. I. (2016 ). Nucleation and Growth of Ordered Arrays of Silver Nanoparticles on Peptide Nanofibers: Hybrid Nanostructures with Antimicrobial Properties. J. Am. Chem. Soc. 138, 5507–5510.
Not in our library10.1021/jacs.6b01570
253.
Pedras M. S. C. Ismail N. Quail J. W. Boyetchko S. M. (2003 ). Structure, Chemistry, and Biological Activity of Pseudophomins A and B, New Cyclic Lipodepsipeptides Isolated from the Biocontrol Bacterium. Pseudomonas Fluorescens. Phytochemistry 62, 1105–1114.
Not in our library10.1016/s0031-9422(02)00617-9
254.
Pelegrini P. B. Quirino B. F. Franco O. L. (2007 ). Plant Cyclotides: an Unusual Class of Defense Compounds. Peptides 28, 1475–1481.
Not in our library10.1016/j.peptides.2007.04.025
255.
Pellegrini A. Thomas U. Bramaz N. Klauser S. Hunziker P. Von Fellenberg R. (1997 ). Identification and Isolation of a Bactericidal Domain in Chicken Egg white Lysozyme. J. Appl. Microbiol. 82, 372–378.
Not in our library10.1046/j.1365-2672.1997.00372.x
256.
Peypoux F. Besson F. Michel G. Delcambe L. (1981 ). Structure of Bacillomycin D, a New Antibiotic of the Iturin Group. Eur. J. Biochem./FEBS 118, 323–327.
Not in our library10.1111/j.1432-1033.1981.tb06405.x
257.
Peypoux F. Bonmatin J. Wallach J. (1999 ). Recent Trends in the Biochemistry of Surfactin. Appl. Microbiol. Biotechnol. 51, 553–563.
Not in our library10.1007/s002530051432
258.
Phillips R. L. Palombo E. A. Panozzo J. F. Bhave M. (2011 ). Puroindolines, Pin Alleles, Purodoindolines and Grain Softness Proteins Are Sources of Bactericidal and Fungicidal Peptides. J. Cereal Sci. 53, 112–117.
Not in our library10.1016/j.jcs.2010.10.005
259.
Pigeon C. Ilyin G. Courselaud B. Leroyer P. Turlin B. Brissot P. (2001 ). A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload. J. Biol. Chem. 276, 7811–7819.
Not in our library10.1074/jbc.m008923200
260.
Ponti D. Mignogna G. Mangoni M. L. De Biase D. Simmaco M. Barra D. (1999 ). Expression and Activity of Cyclic and Linear Analogues of Esculentin-1, an Anti-microbial Peptide from Amphibian Skin. Eur. J. Biochem. 263, 921–927.
Not in our library10.1046/j.1432-1327.1999.00597.x
261.
Porto W. F. Souza V. A. Nolasco D. O. Franco O. L. (2012 ). In Silico identification of Novel Hevein-like Peptide Precursors. Peptides 38, 127–136.
Not in our library10.1016/j.peptides.2012.07.025
262.
Powers J.-P. S. Hancock R. E. W. (2003 ). The Relationship between Peptide Structure and Antibacterial Activity. Peptides 24, 1681–1691.
Not in our library10.1016/j.peptides.2003.08.023
263.
Pulido D. Torrent M. Andreu D. Nogués M. V. Boix E. (2013 ). Two Human Host Defense Ribonucleases against Mycobacteria, the Eosinophil Cationic Protein (RNase 3) and RNase 7. Antimicrob. Agents Chemother. 57, 3797–3805.
Not in our library10.1128/aac.00428-13
264.
Rabanal F. Cajal Y. (2016 ). “Therapeutic Potential of Antimicrobial peptidesSpringer International Publishing: Cham,” in New Weapons to Control Bacterial Growth. Editors Villa T. G. Vinas M., 433–451.Switzerland
Not in our library
265.
Rady I. Siddiqui I. A. Rady M. Mukhtar H. (2017 ). Melittin, a Major Peptide Component of Bee Venom, and its Conjugates in Cancer Therapy. Cancer Lett. 402, 16–31.
Not in our library10.1016/j.canlet.2017.05.010
266.
Raghunath A. Perumal E. (2017 ). Metal Oxide Nanoparticles as Antimicrobial Agents: a Promise for the Future. Int. J. Antimicrob. Agents 49, 137–152.
Not in our library10.1016/j.ijantimicag.2016.11.011
267.
Rajchakit U. Sarojini V. (2017 ). Recent Developments in Antimicrobial-Peptide-Conjugated Gold Nanoparticles. Bioconjug. Chem. 2017 (28), 2673–2686.
Not in our library10.1021/acs.bioconjchem.7b00368
268.
Reed J. D. Edwards D. L. Gonzalez C. F. (1997 ). Synthetic Peptide Combinatorial Libraries: a Method for the Identification of Bioactive Peptides against Phytopathogenic Fungi. Mol. Plant Microbe Interact. 10, 537–549.
Not in our library10.1094/mpmi1997.10.5.537
269.
Robinson W. E. McDougall B. Tran D. Selsted M. E. (1998 ). Anti-HIV-1activity of Indolicidin, an Antimicrobial Peptide from Neutrophils. J. Leukoc. Biol. 63, 94–100.
Not in our library10.1002/jlb.63.1.94
270.
Rosengren K. J. Göransson U. Otvos L. Jr. Craik D. J. (2004 ). Cyclization of Pyrrhocoricin Retains Structural Elements Crucial for the Antimicrobial Activity of the Native Peptide. Biopolymers 76, 446–458.
Not in our library10.1002/bip.20159
271.
Roskoski R. Gevers W. Kleinkauf H. Lipmann F. (1970 ). Tyrocidine Biosynthesis by Three Complementary Fractions from Bacillus Brevis (ATCC 8185). Biochemistry 9, 4839–4845.
Not in our library10.1021/bi00827a002
272.
Rozek A. Powers J-P. S. Friedrich C. L. Hancock R. E. W. (2003 ). Structure-Based Design of an Indolicidin Peptide Analogue with Increased Protease Stability. Biochemistry 42, 14130–14138.
Not in our library10.1021/bi035643g
273.
Runti G. Benincasa M. Giuffrida G. Devescovi G. Venturi V. Gennaro R. (2017 ). The Mechanism of Killing by the Proline-Rich Peptide Bac7(1–35) against Clinical Strains of Pseudomonas aeruginosa Differs from that against Other Gram-Negative Bacteria. Antimicrob. Agents Chemother. 61, e01660–16.
Not in our library10.1128/aac.01660-16
274.
Runti G. Lopez Ruiz M. D. C. Stoilova T. Hussain R. Jennions M. Choudhury H. G. (2013 ). Functional Characterization of SbmA, a Bacterial Inner Membrane Transporter Required for Importing the Antimicrobial Peptide Bac7(1-35). J. Bacteriol. 195, 5343–5351.
Not in our library10.1128/jb.00818-13
275.
Saito Y. Konnai S. Yamada S. Imamura S. Nishikado H. Ito T. (2009 ). Identification and Characterization of Antimicrobial Peptide, Defensin, in the Taiga Tick. Ixodes Persulcatus. Insect Mol. Biol. 18, 531–539.
Not in our library10.1111/j.1365-2583.2009.00897.x
276.
Salick D. A. Kretsinger J. K. Pochan D. J. Schneider J. P. (2007 ). Inherent Antibacterial Activity of a Peptide-Based Beta-Hairpin Hydrogel. J. Am. Chem. Soc. 129, 14793–14799.
Not in our library10.1021/ja076300z
277.
Salick D. A. Pochan D. J. Schneider J. P. (2009 ). Design of an Injectable β-hairpin Peptide Hydrogel that Kills Methicillin-Resistant Staphylococcus aureus. Adv. Mater. 21, 4120–4123.
Not in our library10.1002/adma.200900189
278.
Sarkar B. Siddiqui Z. Nguyen P. K. Namita Dube N. Fu W. (2019 ). Membrane-disrupting Nanofibrous Peptide Hydrogels. ACS Biomater. Sci. Eng. 5, 4657–4670.
Not in our library10.1021/acsbiomaterials.9b0096
279.
Satomi T. Kusakabe H. Nakamura G. Nishio T. Uramoto M. Isono K. (1982 ). Neopeptins A and B, New Antifungal Antibiotics. Agric. Biol. Chem. 46, 2621–2623.
Not in our library10.1080/00021369.1982.10865486
280.
Schauber J. Gallo R. L. (2008 ). Antimicrobial Peptides and the Skin Immune Defense System. J. Allergy Clin. Immunol. 122, 261–266.
Not in our library10.1016/j.jaci.2008.03.027
281.
Schibli D. J. Epand R. F. Vogel H. J. Epand R. M. (2002 ). Tryptophan-rich Antimicrobial Peptides: Comparative Properties and Membrane Interactions. Biochem. Cel Biol. 80, 667–677.
Not in our library10.1139/o02-147
282.
Schmidtche A. Pasupuleti M. Malmsten M. (2014 ). Effect of Hydrophobic Modifications in Antimicrobial Peptides. Adv. Colloid Interf. Sci. 205, 265–274.
Not in our library10.1016/j.cis.2013.06.009
283.
Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity · 2017
No notice
284.
Scocchi M. Mardirossian M. Runti G. Benincasa M. (2016 ). Non-membrane Permeabilizing Modes of Action of Antimicrobial Peptides on Bacteria. Curr. Top. Med. Chem. 16, 76–88.
Not in our library10.2174/1568026615666150703121009
285.
Scott M. G. Davidson D. J. Gold M. R. Bowdish D. Hancock R. E. W. (2002 ). The Human Antimicrobial Peptide Ll-37 Is a Multifunctional Modulator of Innate Immune Responses. J. Immunol. 169, 3883–3891.
Not in our library10.4049/jimmunol.169.7.3883
286.
Segura A. Moreno M. Molina A. García-Olmedo F. (1998 ). Novel Defensin Subfamily from Spinach (Spinacia Oleracea). FEBS Lett. 435, 159–162.
Not in our library10.1016/s0014-5793(98)01060-6
287.
Selim S. Negrel J. Govaerts C. Gianinazzi S. van Tuinen D. (2005 ). Isolation and Partial Characterization of Antagonistic Peptides Produced by Paenibacillus Sp. Strain B2 Isolated from the. Sorghum Mycorrhizosphere. Appl. Environ. Micro- Biol. 71, 6501–6507.
Not in our library10.1128/aem.71.11.6501-6507.2005
288.
Selsted M. E. (2004 ). Theta-defensins: Cyclic Antimicrobial Peptides Produced by Binary Ligation of Truncated Alpha-Defensins. Curr. Protein Pept. Sci. 5, 365–371.
Not in our library10.2174/1389203043379459
289.
Selsted M. E. Brown D. M. DeLange R. J. Harwig S. S. Lehrer R. I. (1985a ). Primary Structures of Six Antimicrobial Peptides of Rabbit Peritoneal Neutrophils. J. Biol. Chem. 260, 4579–4584.
Not in our library10.1016/s0021-9258(18)89110-4
290.
Selsted M. E. Harwig S. S. Ganz T. Schilling J. W. Lehrer R. I. (1985b ). Primary Structures of Three Human Neutrophil Defensins. J. Clin. Invest. 76, 1436–1439.
Not in our library10.1172/jci112121
291.
Shagaghi N. Palombo E. A. Clayton A. H. A. Bhave M. (2016 ). Archetypal Tryptophan-Rich Antimicrobial Peptides: Properties and Applications. World J. Microbiol. Biotechnol. 32, 31.
Not in our library10.1007/s11274-015-1986-z
292.
Shankar S. S. Benke S. N. Nagendra N. Srivastava P. L. Thulasiram H. V. Gopi H. N. (2013 ). Self-Assembly to Function: Design, Synthesis, and Broad-Spectrum Antimicrobial Properties of Short Hybrid E-Vinylogous Lipopeptides. J. Med. Chem. 56, 8468–8474.
Not in our library10.1021/jm400884w
293.
Shi J. Ross C. R. Chengappa M. M. Sylte M. J. McVey D. S. Blecha F. (1996 ). Antibacterial Activity of a Synthetic Peptide (PR-26) Derived from PR-39, a Proline-Arginine-Rich Neutrophil Antimicrobial Peptide. Antimicrob. Agents Chemother. 40, 115–121.
Not in our library10.1128/aac.40.1.115
294.
Shi W. Li C. Li M. Zong X. Han D. Chen Y. (2016 ). Antimicrobial Peptide Melittin against Xanthomonas Oryzae Pvoryzae, the Bacterial Leaf Blight Pathogen in rice. Appl. Microbiol. Biotechnol. 100, 5059–5067.
Not in our library10.1007/s00253-016-7400-4
295.
Sikorska E. Stachurski O. Neubauer D. Małuch I. Wyrzykowski D. Bauer M. (2018 ). Short Arginine-Rich Lipopeptides: from Self-As- Sembly to Antimicrobial Activity. Biochim. Biophys. Acta Biomembr. 1860, 2242–2251.
Not in our library10.1016/j.bbamem.2018.09.004
296.
Simmaco M. Mignogna G. Barra D. Bossa F. (1994 ). Antimicrobial Peptides from Skin Secretions of Rana esculenta. Molecular Cloning of cDNAs Encoding Esculentin and Brevinins and Isolation of New Active Peptides. J. Biol. Chem. 269, 11956–11961.
Not in our library10.1016/s0021-9258(17)32666-2
297.
Simmaco M. Mignogna G. Canofeni S. Miele R. Mangoni M. L. Barra D. (1996 ). Temporins, Antimicrobial Peptides from the European Red Frog Rana Temporaria. Eur. J. Biochem. 242, 788–792.
Not in our library10.1111/j.1432-1033.1996.0788r.x
298.
Singh M. Singh S. Prasad S. Gambhir I. S. (2008 ). Nanotechnology in Medicine and Antibacterial Effect of Silver Nanoparticles. Dig. J. Nanomater. Biostruct. 3, 115–122.
Not in our library
299.
Singh P. Cameotra S. S. (2004 ). Potential Applications of Microbial Surfactants in Biomedical Sciences. Trends Biotech. 22, 142–146.
Not in our library10.1016/j.tibtech.2004.01.010
300.
Sitaram N. (2006 ). Antimicrobial Peptides with Unusual Amino Acid Compositions and Unusual Structures. Curr. Med. Chem. 13, 679–696.
Not in our library10.2174/092986706776055689
301.
Sitaram N. Nagaraj R. (1999 ). Interaction of Antimicrobial Peptides with Biological and Model Membranes: Structural and Charge Requirements for Activity. Biochim. Biophys. Act. 1462, 29–54.
Not in our library10.1016/s0005-2736(99)00199-6
302.
Smits G. J. Kapteyn J. C. van den Ende H. Klis F. M. (1999 ). Cell wall Dynamics in Yeast. Curr. Opin. Microbiol. 2, 348–352.
Not in our library10.1016/s1369-5274(99)80061-7
303.
Sørensen D. Nielsen T. H. Sørensen J. Christophersen C. (2002 ). Cyclic Lipoundecapeptide Lokisin from Pseudomonas Sp. Strain DSS41. Tetrahedron Lett. 43, 4421–4423.
Not in our library10.1016/s0040-4039(02)00856-0
304.
Spencer J. D. Schwaderer A. L. Wang H. Bartz J. Kline J. Eichler T. (2013 ). Ribonuclease 7, an Antimicrobial Peptide Upregulated during Infection, Contributes to Microbial Defense of the Human Urinary Tract. Kidney Int. 83, 615–625.
Not in our library10.1038/ki.2012.410
305.
Stachurski O. Neubauer D. Małuch I. Wyrzykowski D. Bauer M. Bartoszewska S. (2019 ). Effect of Self-Assembly on Antimicrobial Activity of Double-Chain Short Cationic Lipopeptides. Bioorg. Med. Chem. 27, 115129.
Not in our library10.1016/j.bmc.2019.115129
306.
Stalmans S. Wynendaele E. Bracke N. Knappe D. Hoffmann R. Peremans K. (2014 ). Blood-brain Barrier Transport of Short Proline-Rich Antimicrobial Peptides. Protein Pept. Lett. 21, 399–406.
Not in our library10.2174/09298665113206660110
307.
Stec B. (2006 ). Plant Thionins—The Structural Perspective. Cel. Mol. Life Sci. 63, 1370–1385.
Not in our library10.1007/s00018-005-5574-5
308.
Steenbergen J. N. Alder J. Thorne G. M. Tally F. P. (2005 ). Daptomycin: a Lipopeptide Antibiotic for the Treatment of Serious Gram-Positive Infections. J. Antimicrob. Chemother. 55 (2005), 283–288.
Not in our library10.1093/jac/dkh546
309.
Steffen H. Rieg S. Wiedemann I. Kalbacher H. Deeg M. Sahl H.-G. (2006 ). Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge. Antimicrob. Agents Chemother. 50, 2608–2620.
Not in our library10.1128/aac.00181-06
310.
Stein T. (2005 ). Bacillus Subtilis Antibiotics: Structures, Syntheses and Specific Functions. Mol. Microbiol. 56, 845–857.
Not in our library10.1111/j.1365-2958.2005.04587.x
311.
Steiner H. Hultmark D. Engstrom A. Bennich H. Boman H. G. (1981 ). Sequence and Specificity of Two Antibacterial Proteins Involved in Insect Immunity. Nature 292, 246–248.
Not in our library10.1038/292246a0
312.
Subbalakshmi C. Sitaram N. (1998 ). Mechanism of Antimicrobial Action of Indolicidin. FEMS Microbiol. Lett. 160, 91–96.
Not in our library10.1111/j.1574-6968.1998.tb12896.x
313.
Svenson J. Karstad R. Flaten G. E. Brandsdal B. O. Brandl M. Svendsen J. S. (2009 ). Altered Activity and Physicochemical Properties of Short Cationic Antimicrobial Peptides by Incorporation of Arginine Analogues. Mol. Pharmaceutics 6, 996–1005.
Not in our library10.1021/mp900057k
314.
Takesako K. Ikai K. Haruna F. Endo M. Shimanaka K. Sono E. (1991 ). Aureobasidins, New Antifungal Antibiotics. Taxonomy, Fermentation, Isolation, and Properties. J. Antibiot. 44, 919–924.
Not in our library10.7164/antibiotics.44.919
315.
Tam C. Mun J. J. Evans D. J. Fleiszig S. M. (2012 ). Cytokeratins Mediate Epithelial Innate Defense through Their Antimicrobial Properties. J. Clin. Invest. 122, 3665–3677.
Not in our library10.1172/jci64416
316.
Tam J. P. Lu Y-A. Yang J-L. (2000 ). Design of Salt-Insensitive Glycine-Rich Antimicrobial Peptides with Cyclic Tricystine Structures. Biochemistry 39, 7159–7169.
Not in our library10.1021/bi0003487
317.
Tam J. P. Lu Y. A. Yang J. L. (2002 ). Antimicrobial Dendrimeric Peptides. Eur. J. Biochem. 269, 923–932.
Not in our library10.1046/j.0014-2956.2001.02728.x
318.
Antimicrobial Peptides from Plants · 2015
No notice
319.
Tang Y. Q. Yuan J. Osapay G. Osapay K. Tran D. Miller C. J. (1999 ). A Cyclic Antimicrobial Peptide Produced in Primate Leukocytes by the Ligation of Two Truncated Alpha-Defensins. Science 286, 498–502.
Not in our library10.1126/science.286.5439.498
320.
Thimon L. Peyoux F. Maget-Dana R. Michel G. (1992 ). Surface-active Properties of Antifungal Lipopeptides Produced by. Bacillus Subtilis. J. Am. Oil. Chem. Soc. 69, 92–93.
Not in our library10.1007/bf02635884
321.
Timmerman P. Beld J. Puijk W. C. Meloen R. H. (2005 ). Rapid and Quantitative Cyclization of Multiple Peptide Loops onto Synthetic Scaffolds for Structural Mimicry of Protein Surfaces. Chem. Bio Chem. 6, 821–824.
Not in our library10.1002/cbic.200400374
322.
Tomita M. Takase M. Bellamy W. Shimamura S. (1994 ). A Review: The Active Peptide of Lactoferrin. Pediatr. Int. 36, 585–591.
Not in our library10.1111/j.1442-200x.1994.tb03250.x
323.
Tran H. Ficke A. Asiimwe T. Höfte M. Raaijmakers J. M. (2007 ). Role of the Cyclic Lipopeptide Massetolide A in Biological Control of Phytophthora Infestans and in Colonization of Tomato Plants by. Pseudomonas Fluorescens. New Phytol. 175, 731–742.
Not in our library10.1111/j.1469-8137.2007.02138.x
324.
Van der Weerden N. L. Hancock R. E. Anderson M. A. (2010 ). Permeabilization of fungal hyphae by the plant defensin NaD1 occurs through a cell wall-dependent process. J. Biol. Chem. 285, 37513–37520.
Not in our library10.1074/jbc.m110.134882
325.
Van Parijs J. Broekaert W. F. Goldstein I. J. Peumans W. J. (1991 ). Hevein an Antifungal Protein from Rubber-Tree (Hevea Braziliensis) Latex. Planta 183, 258–264.
Not in our library10.1007/bf00197797
326.
Vanittanakom N. Loeffler W. Koch U. Jung G. (1986 ). Fengycin - a Novel Antifungal Lipopeptide Antibiotic Produced by Bacillus Subtilis F-29-3. J. Antibiot. (Tokyo). 39, 888–901.
Not in our library10.7164/antibiotics.39.888
327.
Vasu S. McGahon M. K. Moett R. C. Curtis T. M. Conlon J. M. Abdel-Wahab Y. H. A. (2017a ). Esculentin-2CHa(1–30) and its Analogues: Stability and Mechanisms of Insulinotropic Action. J. Endocrinol. 232, 423–435.
Not in our library10.1530/joe-16-0453
328.
Vasu S. Ojo O. O. Moffett R. C. Conlon J. M. Flatt P. R. Abdel-Wahab Y. H. A. (2017b ). Anti-diabetic Actions of esculentin-2CHa(1–30) and its Stable Analogues in a Diet-Induced Model of Obesity-Diabetes. Amino Acids 49, 1705–1717.
Not in our library10.1007/s00726-017-2469-3
329.
Veiga A. S. Sinthuvanich C. Gaspar D. Franquelim H. G. Castanho M. R. B. Schneider J. P. (2012 ). Arginine-rich Self-Assembling Peptides as Potent Antibacterial Gels. Biomaterials 33, 8907–8916.
Not in our library10.1016/j.biomaterials.2012.08.046
330.
Ventola C. L. (2015 ). The Antibiotic Resistance Crisis Part 1: Causes and Threats. P T. 40, 277–283.
Not in our library
331.
Vijayakumar E. Roy K. Chatterjee S. Deshmukh S. Ganguli B. Fehlhaber H.-W. (1996 ). Arthrichitin. A. New Cell Wall Active Metabolite Arthrinium Phaeospermum. J. Org. Chem. 61, 6591–6593.
Not in our library10.1021/jo960769n
332.
Vunnam S. Juvvadi P. Rotondi K. S. Merrifield R. B. (1998 ). Synthesis and Study of normal, Enantio, Retro, and Retroenantio Isomers of Cecropin A-Melittin Hybrids, Their End Group Effects and Selective Enzyme Inactivation. J. Pept. Res. 51, 38–44.
Not in our library10.1111/j.1399-3011.1998.tb00414.x
333.
Waghu F. H. Thomas S. I. (2020 ). Collection of Antimicrobial Peptides Database and its Derivatives: Applications and beyond. Protein Sci. 29, 36–42.
Not in our library10.1002/pro.3714
334.
Wakabayashi H. Takase M. Tomita M. (2003 ). Lactoferricin Derived from Milk Protein Lactoferrin. Curr. Pharm. Des. 9, 1277–1287.
Not in our library10.2174/1381612033454829
335.
Walton R. B. Woodruff H. B. (1949 ). A Crystalline Antifungal Agent, Mycosubtilin, Isolated from. Subtilin Broth. J. Clin. Invest. 28, 924–926.
Not in our library10.1172/jci102180
336.
Human Antimicrobial Peptides and Proteins · 2014
No notice
337.
Wang G. Li X. Wang Z. (2016 ). APD3: The Antimicrobial Peptide Database as a Tool for Research and Education. Nucleic Acids Res. 44, D1087–D1093.
Not in our library10.1093/nar/gkv1278
338.
Wang J. Yu Y. Tang K. Liu W. He X. Huang X. (2010 ). Identication and Analysis of the Biosynthetic Gene Cluster Encoding the Thiopeptide Antibiotic Cyclothiazomycin in Streptomyces Hygroscopicus 10-22. Appl. Environ. Microbiol. 76, 2335–2344.
Not in our library10.1128/aem.01790-09
339.
Wiedman G. Fuselier T. He J. Searson P. C. Hristova K. Wimley W. C. (2014 ). Highly Efficient Macromolecule-Sized Poration of Lipid Bilayers by a Synthetically Evolved Peptide. J. Am. Chem. Soc. 136, 4724–4731.
Not in our library10.1021/ja500462s
340.
Wijaya R. Neumann G. M. Condron R. Hughes A. B. Polya G. M. (2000 ). Defense Proteins from Seed of cassia Fistula Include a Lipid Transfer Protein Homologue and a Protease Inhibitory Plant Defensin. Plant Sci. 159, 243–255.
Not in our library10.1016/s0168-9452(00)00348-4
341.
Won H.-S. Kang S.-J. Choi W.-S. Lee B.-J. (2011 ). Activity Optimization of an Undecapeptide Analogue Derived from a Frog-Skin Antimicrobial Peptide. Mol. Cell 31, 49–54.
Not in our library10.1007/s10059-011-0005-y
342.
Wong J. H. Ng T. B. (2005 ). Sesquin, a Potent Defensin-like Antimicrobial Peptide from Ground Beans with Inhibitory Activities toward Tumor Cells and HIV-1 Reverse Transcriptase. Peptides 26, 1120–1126.
Not in our library10.1016/j.peptides.2005.01.003
343.
Yamasaki K. Schauber J. Coda A. Lin H. Dorschner R. A. Schechter N. M. (2006 ). Kallikrein-mediated Proteolysis Regulates the Antimicrobial Effects of Cathelicidins in Skin. FASEB J. 20, 2068–2080.
Not in our library10.1096/fj.06-6075com
344.
Yang C. Boone L. Nguyen T. X. Rudolph D. Limpakarnjanarat K. Mastro T. D. (2005 ). Theta-Defensin Pseudogenes in HIV-1-Exposed, Persistently Seronegative Female Sex-Workers from Thailand. Infect. Genet. Evol. 5, 11–15.
Not in our library10.1016/j.meegid.2004.05.006
345.
Yi G. S. Park C. B. Kim S. C. Cheong C. (1996 ). Solution Structure of an Antimicrobial Peptide Buforin II. FEBS Lett. 398, 87–90.
Not in our library10.1016/s0014-5793(96)01193-3
346.
Yu G. Baeder Desiree Y. Regoes R. R. Rolff J. (2018 ). Predicting Drug Resistance Evolution: Insights from Antimicrobial Peptides and Antibiotics. Proc. R. Soc. Lond. B Biol. Sci. 285, 20172687.
Not in our library10.1098/rspb.2017.2687
347.
Yu H. Y. Tu C. H. Yip B. S. Chen H. L. Cheng H. T. Huang K. C. (2011 ). Easy Strategy to Increase Salt Resistance of Antimicrobial Peptides. Antimicrob. Agents Chemother. 55, 4918–4921.
Not in our library10.1128/aac.00202-11
348.
Zahn M. Berthold N. Kieslich B. Knappe D. Hoffmann R. Sträter N. (2013 ). Structural Studies on the Forward and Reverse Binding Modes of Peptides to the Chaperone DnaK. J. Mol. Bio 425, 2463–2479.
Not in our library10.1016/j.jmb.2013.03.041
349.
Zanjani N. T. Miranda-Saksena M. Cunningham A. L. Dehghani F. (2018 ). Antimicrobial Peptides of marine Crustaceans: The Potential and Challenges of Developing Therapeutic Agents. Curr. Med. Chem. 25, 2245–2259.
Not in our library10.2174/0929867324666171106155936
350.
Zasloff M. (1987 ). Magainins, a Class of Antimicrobial Peptides from Xenopus Skin: Isolation, Characterization of Two Active Forms, and Partial cDNA Sequence of a Precursor. Proc. Natl. Acad. Sci. USA. 84, 5449–5453.
Not in our library10.1073/pnas.84.15.5449
351.
Zhang L. Benz R. Hancock R. E. (1999 ). Influence of Proline Residues on the Antibacterial and Synergistic Activities of α-helical Peptides. Biochemistry 38, 8102–8111.
Not in our library10.1021/bi9904104
352.
Zhang S. K. Ma Q. Li S. B. Gao H. W. Tan Y. X. Gong F. (2016 ). RV-23, a Melittin-Related Peptide with Cell-Selective Antibacterial Activity and High Hemocompatibility. J. Microbiol. Biotechnol. 26, 1046–1056.
Not in our library10.4014/jmb.1510.10074
353.
Zhong C. Zhu N. Zhu Y. Liu T. Gou S. Xie J. (2020 ). Antimicrobial Peptides Conjugated with Fatty Acids on the Side Chain of D-Amino Acid Promises Antimicrobial Potency against Multidrug-Resistant Bacteria. Eur. J. Pharm. Sci. 141, 105123.
Not in our library10.1016/j.ejps.2019.105123

Cited by papers we hold 1

Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.